Front. Plant Sci. Frontiers in Plant Science Front. Plant Sci. 1664-462X Frontiers Media S.A. 10.3389/fpls.2022.780257 Plant Science Review Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand Farmanpour-Kalalagh Karim 1 Beyraghdar Kashkooli Arman 1 * Babaei Alireza 1 Rezaei Ali 1 van der Krol Alexander R. 2 1Department of Horticultural Science, Faculty of Agriculture, Tarbiat Modares University, Tehran, Iran 2Laboratory of Plant Physiology, Wageningen University and Research, Wageningen, Netherlands

Edited by: Linda Avesani, University of Verona, Italy

Reviewed by: Juan Moisés De La Serna, Universidad Internacional De La Rioja, Spain; Stefano Negri, University of Verona, Italy

 *Correspondence: Arman Beyraghdar Kashkooli, a.beyraghdar@modares.ac.ir

This article was submitted to Plant Biotechnology, a section of the journal Frontiers in Plant Science

 07 02 2022 2022 13 780257 20 09 2021 03 01 2022 Copyright © 2022 Farmanpour-Kalalagh, Beyraghdar Kashkooli, Babaei, Rezaei and van der Krol. 2022 Farmanpour-Kalalagh, Beyraghdar Kashkooli, Babaei, Rezaei and van der Krol

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Artemisinin is a natural bioactive sesquiterpene lactone containing an unusual endoperoxide 1, 2, 4-trioxane ring. It is derived from the herbal medicinal plant Artemisia annua and is best known for its use in treatment of malaria. However, recent studies also indicate the potential for artemisinin and related compounds, commonly referred to as artemisinins, in combating viral infections, inflammation and certain cancers. Moreover, the different potential modes of action of artemisinins make these compounds also potentially relevant to the challenges the world faces in the COVID-19 pandemic. Initial studies indicate positive effects of artemisinin or Artemisia spp. extracts to combat SARS-CoV-2 infection or COVID-19 related symptoms and WHO-supervised clinical studies on the potential of artemisinins to combat COVID-19 are now in progress. However, implementing multiple potential new uses of artemisinins will require effective solutions to boost production, either by enhancing synthesis in A. annua itself or through biotechnological engineering in alternative biosynthesis platforms. Because of this renewed interest in artemisinin and its derivatives, here we review its modes of action, its potential application in different diseases including COVID-19, its biosynthesis and future options to boost production.

 Graphical Abstract

Three anti-SARS-CoV-2 potentials of artemisinin and artesunate. Artemisinin (ART) and artesunate (AS) may (1) block interaction of viral spike protein with the human ACE2 receptors, preventing viral endocytosis and activation of the NF-κB signaling pathway, (2) ART and AS may block activation of NF-κB signaling pathway by IKK, or (3) may interfere directly with p50/p65 transcriptional activity in human cells.

 Artemisia annua artemisinin COVID-19 malaria SARS-CoV-2 sesquiterpene lactone Introduction

Artemisinin is an oxygenated sesquiterpene lactone, mostly produced in glandular trichomes (GTs) of the medicinal plant Artemisia annua L. (Tang et al., 2014; Wang et al., 2016; Beyraghdar Kashkooli et al., 2018, 2019). Artemisinin and related compounds derived from the biosynthetic pathway (Figure 1) have been shown to be effective against malaria caused by the Plasmodium spp. parasite (Klayman, 1985; Tu, 2011). The action of artemisinin is not only on the Plasmodium itself, but also because of its effect on human physiology. It is the effects of artemisinin on human physiology that relate to its potential uses in other diseases as well. Below the mode of action of artemisinin and related compounds in Plasmodium and humans are discussed, exemplified by its potential use in the fight against COVID-19.

Chemical structure of artemisinin and related compounds: artemisinin (A), dihydroartemisinin, another biosynthetic pathway product and also known as dihydroqinghaosu, or artenimol (B) and artesunate, which is a semi-synthetic chemical derivative of artemisinin biosynthetic pathway product (C).

Because of the alternative uses of artemisinin, including the fight against COVID-19, the renewed demand for this compound cannot be met by current production capacity. Therefore, also current production capacity problems and potential solutions are briefly discussed.

 Artemisinin: Modes of Action in the Malaria <italic>Plasmodium</italic> Parasitic Cells

Artemisinin contains an endoperoxide bridge that is important for anti-malarial activity. In general, several mechanisms of actions have been proposed to explain the bioactivity of artemisinin against Plasmodium spp. (O’Neill et al., 2010). The first proposed action is the interference with Plasmodium mitochondrial and plasma functions (Antoine et al., 2014). Studies have shown that artemisinin/artemisinin semi-synthetic derivatives (totally known as endoperoxides) induce Plasmodium mitochondrial and plasma membrane depolarization (Wang J. et al., 2010; Antoine et al., 2014). These membrane depolarizations are strongly associated with Reactive Oxygen Species (ROS) that are generated by iron bioactivation of the endoperoxides of artemisinin (Antoine et al., 2014; Wang J. et al., 2015; Tilley et al., 2016). An additional mode of action of artemisinin against the onset of malaria is based on the cleavage of the endoperoxide in the artemisinin molecule, resulting in artemisinin free radicals, which act as alkylation agent for susceptible molecules and proteins in the parasitic cell. For instance, the alkylation of Plasmodium falciparum TCTP, ATP6 (a Ca2+ transporter) (Shandilya et al., 2013) and PI3K (Mbengue et al., 2015) may interfere with the biological function of these proteins in the infection process. In infected red blood cells, the malaria parasite degrades hemoglobin (as a source of amino acids), resulting in large amounts of free heme molecules. These are potentially toxic to the malaria parasite but are detoxified by the parasite via conversion of heme to hemozoin. The alkylation of heme by activated artemisinin could inhibit this detoxification reaction to hemozoin. In a more general sense, the alkylation of parasitic proteins may also interfere with their correct folding, which in turn may be linked to decreased parasite development. Indeed, treatment with artemisinin results in an upregulation of the Unfolded Protein Response (UPR) (Mok et al., 2015). In addition to artemisinin, dihydroartemisinin attacks parasites by using a two-pronged process, creating protein damage, and endangering parasite proteasome function. The consequent gradual accumulation of proteasome substrates (i.e., polyubiquitinated and unfolded/damaged proteins) results in the endoplasmic reticulum stress and dihydroartemisinin-mediated death of the parasite. Tests with other specific inhibitors of the proteasome create a similar increase of polyubiquitinated proteins, also causing parasite death (Bridgford et al., 2018) (Figure 2).

Artemisinin mechanism of action against malaria parasite; (i) production of ROS for depolarization of the parasite’s mitochondria, (ii) interference with the heme detoxification pathway of red blood cells (iii) induction of alkylation and inhibition of cellular elements such as PfATPase6 and (iv) via protein damage, and inhibition of parasite proteasome function.

 Artemisinins: Potential Modes of Action in Human Inflammation Responses

Besides its role in combating malaria, artemisinin has also been investigated for its potential effect on immune responses under physiological and pathological conditions (Efferth et al., 2002; Aldieri et al., 2003; Xu et al., 2007; Gu et al., 2012; Lai et al., 2015; Yu et al., 2016; Nunes et al., 2017). Many bacteria and viruses, including the SARS-CoV-2, activate the NF-κB (Nuclear Factor kappa B) signaling pathway in human cells. NF-κB is a transcription factor that regulates multiple aspects of innate and adaptive immune functions and has a central role in inflammatory responses. For instance, NF-κB induces the expression of pro-inflammatory genes like those encoding cytokines and chemokines. NF-κB is a heterodimeric protein complex consisting of p50/p65 which is retained in the cytosol by interaction with IκBα (Verma et al., 1995). Activation of NF-κB signaling activates the IκB kinase activity which results in the release of p50/p65 from IκBα and subsequent movement of p50/p65 to the nucleus where it leads to the expression of specific genes and the production of pro-inflammatory chemokines and cytokines like Interleukin 6 (IL-6) (Verma et al., 1995; Pahl, 1999; Xiong et al., 2010; Liu et al., 2017; Figure 2). IL-6, is a pleiotropic cytokine that is produced in response to infection, tissue-damaging, cellular immune response, and hematopoiesis to contribute and help the host’s defense system (Tanaka et al., 2014; Velazquez-Salinas et al., 2019). Normally, the production of IL-6 is strictly regulated at transcriptional and post-transcriptional levels. However, certain diseases, like in COVID-19, may cause misregulation of the NF-κB signaling, causing overproduction of IL-6 and other cytokines in a cytokine release syndrome (CRS) (Tanaka et al., 2014; Conti and Younes, 2020; Krishna et al., 2021). Indeed, the dynamic change of IL-6 level can be used as a potential biomarker for a severe case of COVID-19 (Liu et al., 2020; Ulhaq and Soraya, 2020; Zhu et al., 2020). In addition to IL-6, also other factors including interferon γ, tumor necrosis factor (TNF), and Interleukin 1 (IL-1), etc., are over-produced during CRS and contribute to pathophysiological processes and multi-organ dysfunction (MOD) (Krishna et al., 2021). The cytokine storm (CS) during CRS may be brought under control by artemisinin or artesunate treatment as these block NF-κB signaling by inhibiting IKK activity (Efferth et al., 2002; Aldieri et al., 2003; Xu et al., 2007; Gu et al., 2012; Lai et al., 2015; Nunes et al., 2017; Efferth and Oesch, 2021). The activation of NF-κB signaling results in the downstream activation of the p50/p65 transcription factors, and artemisinin and artesunate may also act as an inhibitor in the NF-κB signaling pathway by blocking the function of p50/p65 in transcriptional activation of target genes like IL-6.

 Artemisinins: Potential Modes of Action in Fighting Human Cancers

Artemisinins have been used to combat many different types of cancers and different modes of action have been described (Table 1). One of the most important mechanisms is preventing the activation of NF-κB signaling pathway involved in tumor induction, initiation, and progression of many cancerous cell lines. It is noteworthy that artemisinin may affect NF-κB signaling at different levels: it inhibits initiation of nuclear signaling by preventing interaction of p65 and p50 to cytosolic IKK, but in the nucleus it also inhibits interaction of p50 and p65 with target promoters (Tran et al., 2014) (see GRAPHICAL ABSTRACT). Also, Helicobacter pylori-induced gastric oncogenesis is inhibited by artemisinins through blocking NF-κB signaling. Remarkably in gastric cancer, artemisinins reverse the IκBα level, prevent NF-κB pathway in a dose-dependent manner, and decrease the generation of downstream inflammatory factors such as TNF-α (tumor necrosis factor-α) and IL-8 (interleukin-8) (Su et al., 2019). The artemisinin related compound dihydroartemisinin induces autophagy via suppressing NF-κB pathway in myeloma, colorectal, and cervical cancer cell lines (Hu et al., 2014), while the anti-invasive activity of dihydroartemisinin may occur through preventing of PKCa/Raf/ERK and JNK phosphorylation and decreasing NF-κB (Hwang et al., 2010). Indeed, increasing IkBα protein and blocking p65 subunit in NF-κB pathway is boosted by dihydroartemisinin (Dong et al., 2014).

Artemisinins effects/mechanisms of action in combating various cancers.

Artemisinins type Type of cancer Effects / Mechanism of action References
Artemisinin Renal Inhibition of protein kinase B Yu et al. (2019)
Artemisinin Breast Enhancing of the anti-tumor immune response in 4T1 cancer cells Cao et al. (2019)
Artemisinin Breast Inhibiting osteoclast formation Li J. et al. (2019)
Artemisinin Breast Decreasing functional levels of estrogen receptor-alpha and ablating estrogen-induced proliferation Sundar et al. (2008)
Artemisinin Breast Delaying the development of 7,12-dimethylbenz[a]anthracene (DMBA) Lai and Singh (2006)
Artemisinin Breast Downregulating expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes Tin et al. (2012)
Artemisinin Breast Reducing the number of regulatory T cells Langroudi et al. (2010)
Artemisinin+Transferrin Breast Retarding growth of cancer tumors Lai et al. (2009)
Artemisinin Fibrosarcoma tumors Inducing apoptosis in cancer cells Singh and Lai (2004)
Artemisinin Ovarian Inducing reversal of EMT Liang et al. (2019)
Artemisinin Prostate Blocks cancer growth and cell cycle progression by disrupting sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression Willoughby et al. (2009)
Artemisinin Colon Inducing doxorubicin resistance in cancer cells via calcium-dependent activation of HIF-1α and P-glycoprotein Riganti et al. (2009)
Artemisinin Cervical Repressing telomerase subunits and inducing apoptosis Mondal and Chatterji (2015)
Artemisinin Ishikawa endometrial Triggering a G1 cell cycle arrest of cancer cells, inhibiting cyclin dependent kinase-4 promoter activity and expression by disrupting NF-kB transcriptional signaling Tran et al. (2014)
Artemisinin Neuroblastoma Reducing cell proliferation and inducing apoptosis Zhu et al. (2014)
Artemisinin Nasopharyngeal Down-regulation of BMI-1 cooperates Wu J. et al. (2011)
Artemisinin Gastric Upregulation of p53 Zhang et al. (2014)
Artemisinins Various Cancers Inducing iron-dependent cell death (ferroptosis) in tumor cells Ooko et al. (2015)
Artemisinins Various Cancers Inhibition of tumor angiogenesis Anfosso et al. (2006)
Artemisinins Colorectal Stimulating DR5-specific TRAIL-induced apoptosis by regulating wild type P53 Zhou et al. (2020b)
Artemisinins Gastric Inhibition of NF-κB signaling Su et al. (2019)
Artemisinin+Hyperbaric Oxygen Leukemia Decreasing growth rate of cancer cells Ohgami et al. (2010)
6-Aza-artemisinin Various Cancers In vitro cell-growth inhibitory activities Koi et al. (2020)
Artemisinin+Estrogen Breast and Cervical Antiproliferative activity Fröhlich et al. (2018)
Artemisinin+Artemisinin dimer Breast and Prostate Inducing declines in proteins involved in apoptosis (survivin), cell cycling (cyclin D1), oncogenesis [c-myelocytomatosis oncogene product (c-MYC)], and dysregulated WNT signaling (beta-catenin) Gong et al. (2013)
Artemisinin-tagged Holotransferrin Leukemia Killing cancer cells Lai et al. (2005)
Artemisinin+Artesunate Lung Elevating intracellular ROS and DNA damage Li et al. (2018)
Artemisinin+Transferrin Prostate Induction of apoptosis Nakase et al. (2009)
Artesunate Cancer stem cells Mitochondrial dysfunction of stem cells Subedi et al. (2016)
Artesunate Prostate Targeting NF-kappa B Signaling Nunes et al. (2017)
Artesunate Prostate Suppressing the viability and mobility of cancer cells through UCA1, the sponge of miR-184 Zhou et al. (2017)
Artesunate Head and Neck Inducing ferroptosis in cancer cells by decreasing cellular GSH levels, increasing lipid ROS levels, and activation of Nrf2–antioxidant response element pathway in cancer cells Roh et al. (2017)
Artesunate HeLa cervical cancer cells Mitochondrial fission, autophagy induction, and activating of the PINK1-dependent pathway Zhang et al. (2018)
Artesunate Cervical Inhibiting PGE2 production and Foxp3 expression Zhang et al. (2014)
Artesunate Cervical Inducing radiosensitivity Luo et al. (2014)
Artesunate Cervical Enhancing TRAIL-induced apoptosis in cancer cells through inhibition of the NF-κB and PI3K/Akt signaling pathways Thanaketpaisarn et al. (2011)
Artesunate Colorectal Reducing Ki67 and increasing CD31 expression Krishna et al. (2015)
Artesunate Colorectal Down-regulating immunosuppression from Colon26 and RKO cells by decreasing transforming growth factor β1 and interleukin-10 Cui et al. (2015)
Artesunate Colorectal Expression of beta-catenin and E-cadherin Li et al. (2008)
Artesunate Colorectal Attenuating the growth of cancer cells and inhibiting hyperactive Wnt/b-catenin pathway Li et al. (2007)
Artesunate Colorectal Suppressing inflammation and oxidative stress Kumar et al. (2019)
Artesunate Colorectal Activating the intrinsic apoptosis of HCT116 cells through the suppression of fatty acid synthesis and the NF-κB Pathway Chen et al. (2017)
Artesunate Colorectal Down-regulating of β-catenin, suppressing of angiogenesis, cellular proliferating and inducing of apoptosis Verma et al. (2017)
Artesunate Bladder Inducing autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis (Zhou et al., 2020a)
Artesunate Leukemia Inhibiting angiogenesis and down-regulating vascular endothelial growth factor expression Zhou et al. (2007)
Artesunate T-cell leukemia/lymphoma Increasing of intracellular ROS and activation of the DNA damage marker γ-H2AX Ishikawa et al. (2020)
Artesunate Skin Induction of G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis Jiang et al. (2012)
Artesunate Liver Inducing G0/G1 cell cycle arrest and apoptosis via increasing intracellular ROS Yin et al. (2020)
Artesunate Liver Mitigating proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase Zeng and Zhang (2011)
Artesunate Laryngeal Reducing of tumor proliferation Singh and Verma (2002)
Artesunate Ovarian Promoting Th1 differentiation from CD4+ T cells to enhance cell apoptosis via miR-142 Chen et al. (2019)
Artesunate Ovarian sensitizing cancer cells to cisplatin by downregulating RAD51 Wang B. et al. (2015)
Artesunate Ovarian Inhibiting cancer cell growth and proliferation Greenshields et al. (2017)
Artesunate Ovarian Reducing cell viability McDowell et al. (2021)
Artesunate Glioblastoma Inducing oxidative DNA damage, sustaining DNA double-strand breaks, and the ATM/ATR damage response Berdelle et al. (2011)
Artesunate Rhabdomyosarcoma Inducing ROS and p38 MAPK-mediated apoptosis and counteracting tumor growth Beccafico et al. (2015)
Artesunate Merkel cell carcinoma Affecting T antigen expression and repressing growth and survival of MCPyV-positive cancer cells Sarma et al. (2020)
Artesunate Breast Inhibition of the growth of MCF-7 tumor cell Dong and Wang (2014)
Artesunate Breast Inducing apoptosis pathway by loading into lipid carriers Tran et al. (2016)
Artesunate Breast Induction of apoptosis Jamalzadeh et al. (2017)
Artesunate Breast Enhancing the efficacy of 5-ALA-based SDT Osaki et al. (2017)
Artesunate Breast Activating mitochondrial apoptosis in cancer cells via iron-catalyzed lysosomal ROS production Hamacher-Brady et al. (2011)
Artesunate Breast Inducing G2/M cell cycle arrest through autophagy induction Chen et al. (2014)
Artesunate Breast Down-regulating the expression of Bcl-2 and HSP70, Enhancing the expression of cleaved caspase-9 in MCF-7 and 4T1 cells Pirali et al. (2020)
Artesunate Breast Promoting G2/M cell cycle arrest in MCF7 cancer cells through ATM activation Wen et al. (2018)
Artesunate Endometrial Suppressing the proliferation and development of estrogen receptor-α-positive in HAND2-dependent pathway Yin et al. (2021)
Artesunate Lung Inhibiting invasion and in vivo metastasis in cancer cells by targeting essential extracellular proteases Rasheed et al. (2010)
Artesunate Lung Expression of EGFR and ABCG2 Ma et al. (2011)
Artesunate Bladder Inducing apoptosis of cancer cells by miR-16 regulation of COX-2 expression Zuo et al. (2014)
Artesunate Bladder Impairing growth in cisplatin-resistant cancer cells by cell cycle arrest, apoptosis and autophagy induction Zhao et al. (2020)
Artesunate Colon Enhancing ablation effect on xenograft cancer cells Hao et al. (2020)
Artesunate Colon Inducing apoptosis and autophagy Jiang et al. (2018)
Artesunate Nitrosodiethylamine mediated experimental hepatocellular model Suppression of IL-6-JAK-STAT signaling Ilamathi et al. (2016)
Artesunate HeLa and HepG2 cells Inducing cell death in cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin Yang et al. (2014)
Artesunate Non-small-cell lung Inhibiting epithelial-mesenchymal transition in cancer cells by down-regulating the expression of BTBD7 Wang et al. (2020)
Artesunate Non-small cell lung Enhancing radiosensitivity cancer cells via increasing NO production to induce cell cycle arrest at G2/M phase Zhao et al. (2011)
Artesunate Pancreatic Inducing AsPC-1 and PaTU8988 cell death Wang K. et al. (2019)
Artesunate Pancreatic Activating of ferroptosis Eling et al. (2015)
Artesunate Gastric Wang et al. (2017)
Artesunate Gastric Inhibiting the growth of cancer cells through the mechanism of promoting oncosis Zhou et al. (2013)
Artesunate Gastric Inhibiting cancer cell growth and inducing apoptosis by down-regulating COX-2 Zhang et al. (2015)
Artesunate B-cell lymphoma Suppressing cancer cell growth and metabolism Våtsveen et al. (2018)
Artesunate Bone metastasis Suppressing RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca2+ - NFATc1 signaling pathway and preventing ovariectomy-induced bone loss Zeng et al. (2017)
Artesunate Esophageal Cell apoptosis and suppressing the proliferation Shi et al. (2015)
Artesunate Esophageal Enhancing radiosensitivity of cancer cells by inhibiting the repair of DNA damage Fei et al. (2018)
Artesunate Dermal fibroblasts Inhibiting myofibroblast formation via induction of apoptosis and antagonism of pro-fibrotic gene expression Larson et al. (2019)
Artesunate+Histone Deacetylase Inhibitors Hepatocellular, Colorectal, Lung, and Pancreatic Elevating heme synthesis via synergistic upregulation of ALAS1 expression Chen et al. (2019)
Artesunate+Ferrous iron Leukemia and Astrocytoma Induction of apoptosis Efferth et al. (2004)
Artesunate+Sorafenib Liver Inhibiting cancer cell growth and apoptosis induction Li H. et al. (2019)
Artesunate+Cisplatin Lung Inhibiting MAPK pathway Li W. et al. (2021)
Artesunate and Dihydroartemisinin Neuroblastoma Inducing apoptosis and ROS in cancer cells Michaelis et al. (2010)
Artesunate+Connexin-43 Renal and Breast DNA damage and enhancing the bystander apoptosis of the neighboring cells Raza et al. (2017)
Artesunate+Allicin Osteosarcoma Inhibiting cell proliferation and apoptosis Jiang et al. (2013)
Artesunate and Dihydroartemisinin Epithelial ovarian Inhibiting epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest and suppressing the cell cycle-related NF-κB-signaling pathway Li et al. (2018)
Dihydroartemisinin Colorectal Potentiation of 5-fluorouracil antitumor activity Yao et al. (2018)
Dihydroartemisinin Colorectal Induction of iron-dependent endoplasmic reticulum stress Lu et al. (2011)
Dihydroartemisinin HeLa cervical cancer cells Autophagy within cancer cells through Bcl-2 phosphorylation at Ser70 Wang L. et al. (2019)
Dihydroartemisinin Cervical Cytotoxic activity against papillomavirus-expressing epithelial cells Disbrow et al. (2005)
Dihydroartemisinin Esophageal Inactivating of NF-κB in Eca109 and Ec9706 Li et al. (2014)
Dihydroartemisinin Esophageal Increasing the sensitivity of photodynamic therapy via NF-κB/HIF-1α/VEGF pathway Li et al. (2018)
Dihydroartemisinin Breast Inducing apoptosis Mao et al. (2013)
Dihydroartemisinin Hepatocellular Inhibiting proliferation and inducing apoptosis of cancer cell by upregulating tumor necrosis factor via JNK/NF-κB pathways Wu et al. (2019)
Dihydroartemisinin Ovarian Inducing apoptosis and inhibiting proliferation, migration, and invasion in cancer cells via inhibition of the hedgehog signaling pathway Liu et al. (2018)
Dihydroartemisinin Ovarian Inhibiting PDGFRα-positive cancer cell growth and metastasis through inducing degradation of PDGFRα protein Li et al. (2017)
Dihydroartemisinin Ovarian Inhibiting cancer cell growth, inducing apoptosis and G2 cell cycle arrest, decreasing of Bcl-xL and Bcl-2, and increasing of Bax and Bad Jiao et al. (2007)
Dihydroartemisinin Various Cancers Inhibiting angiogenesis Chen et al. (2003)
Dihydroartemisinin Cholangiocarcinoma and Hepatocarcinoma Expression of TDR1, MDR1, MRP1, MRP2, and MRP3 Chaijaroenkul et al. (2011)
Dihydroartemisinin Pancreatic Inhibiting cell viability, downregulating the expression of proliferating cell nuclear antigen and cyclin D1, upregulated p21WAF1/CIP1, inducing apoptosis by reducing the ratio of Bcl-2/Bax and increasing the activation of caspase-9 Chen et al. (2009)
Dihydroartemisinin Pancreatic Inducing oncosis-like cell death Du et al. (2010)
Dihydroartemisinin Pancreatic Inducing cell cycle arrest, apoptosis, and inhibiting of NF-kB signaling Chen et al. (2010)
Dihydroartemisinin Pancreatic Inhibiting NF-kB pathway Wang et al. (2011); Wang et al. (2010)
Dihydroartemisinin Non-small-cell lung Suppressing metastasis of cancer via inhibiting NF-κB/GLUT1 axis Jiang J. et al. (2016)
Artemisone Melanoma Inhibiting cancer cell growth Dwivedi et al. (2015)
Artemisone Breast, Colon, Melanoma, and Pancreatic Reducing cell viability and arresting cell cycling Gravett et al. (2011)
Artemether Gastric Increasing of DNA-damage index, inducing necrosis in PG100, inducing both apoptosis and necrosis in lymphocytes Alcântara et al. (2013)
Artesunic acid+Thymoquinone Colorectal Increasing of ROS, and elevating levels of DNA-damage marker γ-H2AX Fröhlich et al. (2017)
Anhydro dihydroartemisinin and 10-dihydroartemisinyl acetate Liver/Colon Antiproliferative and inhibiting the release of BVDV-RNA Blazquez et al. (2013)
Artemisinin, Dihydroartemisinin, and Artesunate Non-small-cell lung Inhibiting tumorigenesis and tumor metastasis through Wnt/β-catenin signaling Tong et al. (2016)

Artesunate attenuates the growth of cancer cells and thus the development of the tumor by targeting NF-κB pathway (Table 1). In prostate cancer cells, resistance to androgen receptor antagonists is reduced by using artesunate. Mechanistically, the combination of artesunate and bicalutamide prevents NF-κB pathway by ubiquitin-mediated proteasomal deterioration (Nunes et al., 2017). In attempts to treat cervical cancer, the evidence demonstrated that artesunate successfully increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity via pro-survival proteins including X-linked inhibitor of apoptosis protein (XIAP), survivin, and B-cell lymphoma-extra-large (Bcl-xL), and reduces the number of survival proteins in HeLa cells. The downregulation of mentioned proteins can be regulated by repressing activation of serine/threonine-protein kinase and NF-κB signaling. Artesunate further prevents TRAIL-influenced transcriptional activity of NF-κB (Thanaketpaisarn et al., 2011).

 Artemisinins: Potentials in Combating COVID-19 and Other Human Viral Infections Physiological Effects of Artemisinins or <italic>Artemisia</italic> spp. Plant Extracts

Currently, we are facing the serious challenge of the COVID-19 pandemic, which has disrupted global health and the economy. COVID-19 is a virus-related disease similar to Severe Acute Respiratory Syndrome CoronaVirus (SARS-CoV) (Lu et al., 2020) and is caused by the SARS-CoV-2 (Lai et al., 2020; Singhal, 2020). Unlike with SARS-CoV, patients infected with SARS-CoV-2 initially have mild symptoms and continue their daily activities, but in the meantime are infectious to others (Heymann and Shindo, 2020; Zheng et al., 2020). In some patients, disease symptoms may suddenly increase dramatically due to the development of a CS entitled CRS with hallmarks in the body of inflammation and immunosuppression (Mehta et al., 2020). CRS in COVID-19 patients may result in respiratory failures that create Acute Respiratory Distress Syndrome (ARDS) and MOD (Krishna et al., 2021). While worldwide efforts are aimed at vaccines that may prevent infection by COVID-19, additional medicines that can alleviate the severe symptoms of COVID-19 are still a high priority, also because new viral variants may escape vaccine recognition.

Previously, in vitro studies have indicated that the alkylating activity of activated artemisinin (as discussed above in the context of malaria) or the specific structure of artemisinin may have potential in preventing infections by members of the Herpesviridae family (e.g., herpes simplex virus type 1, Epstein-Barr virus, human cytomegalovirus), hepatitis B virus, hepatitis C virus, and bovine viral diarrhea virus (Efferth et al., 2008; Efferth, 2018). Artemisinin also has received renewed attention to fight emerging new viruses for which no effective antiviral drugs are available (e.g., HIV, dengue virus, chikungunya virus, Ebola virus), against viral strains that have developed drug resistance (e.g., human cytomegalovirus) and most recently against Corona-virus (D’alessandro et al., 2020). To combat infection by COVID-19, extracts from different medicinal plants (including from Artemisia spp.) have been tested against COVID-19 (Bahrami et al., 2020; Bailly and Vergoten, 2020; Huang et al., 2020; Kapepula et al., 2020; Koshak and Koshak, 2020; Mani et al., 2020; Verma et al., 2020; Williamson and Kerimi, 2020; Belhassan et al., 2021; Hassanipour et al., 2021; Javed et al., 2021; Lyu et al., 2021; Nazrul Islam et al., 2021; Song et al., 2021).

In vitro efficacy of artemisinin-based treatments to combating SARS-CoV-2 has indicated that treatment with artesunate, artemether, A. annua extracts, and artemisinin hindered virus infections of human lung cancer A549-hACE2 cells, VeroE6 cells, and human hepatoma Huh7.5 cells. Among these four treatments, artesunate showed the strongest anti-SARS-CoV-2 activity (7–12 μg/mL), followed by artemether (53–98 μg/mL), A. annua extracts (83–260 μg/mL), and artemisinin (151 to at least 208 μg/mL). Collectively, time-of-addition experiments in A549-hACE2 cells displayed that artesunate attacked the virus at the post-entry level (Zhou et al., 2021). In parallel with the previous study, dried-leaf hot-water extracts of A. annua cultivars including SAM, BUR, A3, and MED revealed in vitro anti-SARS-CoV-2 activity against Alpha, Beta, Gamma, Delta, and Kappa variants of the virus. All cultivars in addition to being potent in combating with original wild type WA1 also showed effective potential against mentioned variants. IC90 and IC50 according to measured artemisinin content ranged from 1.4–25.0 μM and 0.3 to 8.4 μM, respectively. Also, the IC90 and IC50 according to dried-leaf weight ranged from 59.5–160.6 μg DW and 11.0 to 67.7 μg DW, respectively (Nair et al., 2022). Alternatively, Artemisia spp. Extracts and COVID-Organics drink produced in Madagascar hindered in vitro SARS-CoV-2 and Feline coronavirus (FcoV) infections at concentrations that did not influence cell efficacy and viability (Nie et al., 2021).

In another successful in vitro study, six monomer compounds including artesunate, artemether, arteannuin B, andrographolide, licochalcone B, and echinatin exerted high anti-SARS-CoV-2 and anti-GX_P2V (pangolin coronavirus) activity (Hu et al., 2021). In addition to the mentioned monomers, it is noteworthy that the quinoline like artemisinins has shown strong anti-SARS-CoV-2 activity (Firestone et al., 2021). Also, the anti-SARS-CoV-2 activity of nine artemisinin-based compounds experimented in vitro. Results highlighted that arteannuin B, artesunate, and dihydroartemisinin are the most potent agents in inhibiting virus activity. Also, several artemisinins decreased the generating of the virus nucleocapsid (N) proteins in a dose-dependent manner. It can be concluded that targeting N proteins can be considered as one of the possible options to control viral infection. On the other hand, both lumefantrine and arteannuin B suppressed viral infection following SARS-CoV-2 entry toward the host cells (Cao et al., 2020). In addition to artemisinins monotherapy, in vitro inhibition of SARS-CoV-2 replication by artemisinin-based combination therapies (ACTs) in African experimental society indicated that the artesunate-mefloquine exerted high anti-SARS-CoV-2 activity with % inhibition of 72.1 ± 18.3%. Also, other ACTs including artesunate-pyronaridine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine displayed the same range of inhibition (27.1 to 34.1 %) (Gendrot et al., 2020). Along with in vitro studies of ACTs, molecular docking studies have also demonstrated the anti-SARS-CoV-2 activity of artemisinin-thymoquinone hybrids against the main protease of the virus (de Oliveira et al., 2021).

 Molecular Modes of Action of Artemisinins in Combating COVID-19 Blocking Receptor Binding of Spike Protein to Host Cell Surface

While extracts from medicinal plants may show some preliminary efficacy in small scale clinical trials (Dong et al., 2020; reviewed in Orege et al., 2021), these do not clarify where the activity is coming from. For instance, the antiviral and immunomodulation effects of Artemisia spp. Extracts, as recently been reviewed (Kshirsagar and Rao, 2021), may not only be due to artemisinins, but also from other potential bioactive compounds like flavonoids, mono- and sesqui-terpenes or tannins in these extracts (Kshirsagar and Rao, 2021). To address efficiency and potential harmful side effects of plant extracts, a more detailed knowledge on the molecular mode of action of individual bioactive molecules is needed (Cheong et al., 2020; Guastalegname and Vallone, 2020). Studies indicate that artesunate, dihydroartemisinin, and artemisinin may act at the cell surface by inhibition of the binding of the SARS-CoV-2 spike protein to cell surface receptors, thus potentially preventing both endocytosis of the virus and activation of the NF-κB signaling pathway (Gendrot et al., 2020; Rolta et al., 2020; Sehailia and Chemat, 2020; Uckun et al., 2021).

However, molecular docking studies indicate that artemisinins may also bind to coronavirus-host proteins such as E protein, helicase protein, N protein, 3CLPRO, S protein, nonstructural protein 3 (nsp3), nsp10, nsp14, nsp15, cathepsin-L, and glucose-regulated protein 78 receptor (Fuzimoto, 2021; Ribaudo et al., 2021) and part of the biological activity of artemisinin against COVID-19 may thus also be partially based on inhibiting the function of these viral proteins.

 Preventing Cytokine Storm by Inhibiting IKK

In addition, artemisinin/and or artesunate may limit CS by inhibiting IKK and thus over-active NF-κB signaling, or it may inhibit the transcriptional activity of p50/p65, released by NF-κB signaling (see GRAPHICAL ABSTRACT). While preliminary studies with artemisinins look promising, researchers have warned that the potential of artemisinins in combating COVID-19 requires further clinical research (Uzun and Toptas, 2020; Krishna et al., 2021).

 Artemisinins-Related Clinical Trials in Combating COVID-19

A total of 16 trials with Artemisia spp. Extract, artemisinins, and ACTs have been registered in the US National Library of Medicine1 with clinical trial IDs: NCT04530617, NCT04306497, NCT04701606, NCT04695197, NCT04475107, NCT04532931, NCT04374019, NCT05084911, NCT04502342, NCT04801017, NCT04374084, NCT05004753, NCT04387240, NCT04553705, NCT04802382, NCT04382040, and 3 trials in Chinese Clinical Trial Registry (ChiCTR) database2 with IDs: ChiCTR2000033049, ChiCTR2000032915, and ChiCTR2000030082 (suspended by the investigator) to combat SARS-CoV-2 infection.

Until December 2021, only one trial registered in https://clinicaltrials.gov/ has been terminated with ID number: NCT04530617. Preliminary results from this study indicate that the agents such as A. annua and Camostat mesilate may help reduce the number of hospitalized patients and that the use of artemisinin-piperaquine for treatment of COVID-19 is safe (Li et al., 2020). Therefore, the World Health Organization (WHO) has initiated clinical trials on three promising candidate drugs, including artesunate, to evaluate the anti-inflammatory activity against SARS-CoV-2 (Solidarity Trial PLUS is registered at: ISRCTN83971151). As new mutations occur in the SARS-CoV-2, resulting in new variants including Alpha, Beta, Gamma, Delta, Kappa, and Omicron, combating potential downstream effects of COVID-19 infections remains an important aspect of dealing with the ongoing pandemic, especially when this virus has become endemic.

 Natural Artemisinin Production: Low Yield and Alternatives to Boost Production

Artemisinin is produced in glandular trichomes in the leaves and ovary of the A. annua (Wang et al., 2016). Both the specificity of artemisinin biosynthesis occurring in GTs and the fact that GTs represent about 2% of plant total weight put a limit to the bulk production of artemisinin in planta (Judd et al., 2019). The different steps in artemisinin production are shown in Figure 3. The end-product of the enzymatic pathway (dihydroartemisinic acid) is presumably toxic to the plant cell and is therefore exported over the plasma membrane and the cell wall to a subcuticular space where it is converted non-enzymatically by light (UV) to artemisinin (Wang et al., 2016). In parallel, artemisinic acid, another end-product of the enzymatic pathway may also be exported from the cell, and extracellularly converted to arteannuin B. Typical yield of artemisinin from the Artemisia annua plant is 0.6 to 1.2% but may go up to 2% based on plant dry weight (Zhang et al., 2008). However, such yield is low and far from the potential world’s demand (Judd et al., 2019). Current supplies of artemisinin are already limiting to treat people for malaria in a cost-effective way, so use in treating the disease of pandemic proportions like COVID-19 will need new approaches to artemisinin production. Several methods have been proposed to increase artemisinin production so far which are treatments impacting A. annua cultivation and physiology and breeding approaches to increase artemisinin yield, engineering artemisinin biosynthetic and transport pathway in the native A. annua plants, and engineering of heterologous (plant and microorganism) systems via ectopic expression of the biosynthetic pathway (Lei et al., 2011; Liu et al., 2011; Parshikov et al., 2012; Fuentes et al., 2016; Kiani et al., 2016; Ikram and Simonsen, 2017; Carqueijeiro et al., 2020).

A schematic representation of the artemisinin biosynthetic pathway in Artemisia annua L. The precursors for artemisinin biosynthesis (DMAPP and IPP) are produced in the cytosolic Mevalonate (MVA) pathway and the plastidal 2-C-Methylerythritol 4-phosphate pathway (MEP) pathway, respectively (Dewick, 2009; Vranová et al., 2013; Beyraghdar Kashkooli et al., 2019). IPP+DMAPP are converted to FPP, which is the general precursor for sesquiterpenes (Fuentes et al., 2016). In sequential enzymatic steps, FPP is converted to amorphadiene, artemisinin alcohol, artemisinic aldehyde, dihydroartemisinic aldehyde, and finally artemisinic acid. The first and key step in the biosynthesis of artemisinin biosynthetic pathway is the conversion of FPP to amorpha 4, 11-diene (known as amorphadiene), which is catalyzed by a well-known terpene cyclase, the amorpha-4,11-diene synthase (ADS) (Mercke et al., 2000; Bertea et al., 2005). The cytochrome P450 hydroxylase (CYP71AV1) (Teoh et al., 2006) then converts amorphadiene to artemisinic alcohol. CYP71AV1 also oxidizes artemisinic alcohol to artemisinic aldehyde and artemisinic acid, respectively. Artemisinic aldehyde double bond reductase (DBR2) as the branching point and the aldehyde dehydrogenase 1 (ALDH1) (Zhang et al., 2008) convert artemisinic aldehyde to dihydroartemisinic aldehyde and dihydroartemisinic acid, respectively (Bertea et al., 2005; Schramek et al., 2010). Abbreviation for genes in artemisinin biosynthetic pathway includes; GPPS, geranyl pyrophosphate synthase; FPPS, farnesyl pyrophosphate synthase; ADS, armorpha-4, 11-diene synthase; CYP71AV1, cytochrome P450 monooxygenase; CPR, cytochrome P450 reductase; DBR2, artemisinic aldehyde delta-11(13)-double bond reductase; ALDH1, aldehyde dehydrogenase 1.

 Treatments Impacting Artemisinin Content in <italic>Artemisia annua</italic>

Thanks to targeted breeding programs different cultivars of A. annua can be grown in a wide range of climate conditions (temperate, cold temperate, subtropical, and Mediterranean) (Ferreira et al., 2005). However, the content and composition of secondary metabolites in A. annua plants are determined by numerous interacting factors: geographical conditions, harvesting time, agricultural practices (e.g., fertilization, irrigation, density per unit area) and post-harvest conditions (Mert et al., 2002; Jelodar et al., 2014). Conventional manipulations of the A. annua plant that may enhance artemisinin production are discussed below and summarized in Figure 4.

Classical methods to improve artemisinin production in Artemisia annua.

 Nutrient Manipulations

In addition to genetic factors, the artemisinin yield can be influenced by environmental conditions and field management practices (Charles et al., 1991). Furthermore, the use of fertilizer compounds can also affect the artemisinin content. As studies have shown, manure and chemical fertilizers are effective in the production of secondary metabolites by improving the photosynthetic rate and carbon production (Jha et al., 2011). Numerous reports have considered the use of nitrogen (N) fertilizer to be somewhat effective in increasing the artemisinin content (Ferreira et al., 2005; Davies et al., 2009; Aftab et al., 2011). In addition to the important role of macronutrients in increasing the artemisinin production in Artemisia plants, studies showed that the deficiency of micronutrients (iron, copper, zinc, and barium) also plays a significant role in reducing the artemisinin content (Srivastava and Sharma, 1990).

 Biotic Elicitors

Similarly, the use of elicitors in plants increases the accumulation of secondary metabolites (Zhao et al., 2005). For instance, the elicitor of Penicillium chrysogenum extract has increased (up to double) the production of artemisinin in hairy roots of A. annua (Liu et al., 1999). Additionally, the application of chitosan or of the arbuscular mycorrhizal species Rhizophagus intraradices (as elicitor) was able to increase the content of dihydroartemisinic acid and artemisinin in Artemisia plants (Lei et al., 2011; Mandal et al., 2014). Since the response to these biotic factors often involves the phytohormone jasmonic acid (JA), the effect of these factors on artemisinin content could be due to activated JA signaling.

 Plant Breeding

The main breeding goals of A. annua are the improvement of artemisinin production by increasing the yield potential of leaves, proliferate the number of shoots, and raising the total number of glandular trichomes per plant (Graham et al., 2010; Jelodar et al., 2014). Selection through germplasm and genetic modification can be considered as basic strategies for the improvement of artemisinin production in A. annua (Charles et al., 1991; Xie et al., 2016). A very common breeding technique to increase the secondary metabolites is the manipulation of the ploidy levels in plants (Weathers, 2003). The production of artificial polyploids as a plant breeding strategy has made it possible to develop new and improved cultivars (Iannicelli et al., 2020). In this regard, the application of ploidy manipulation techniques has successfully increased the artemisinin production in A. annua. Reports indicate that the amount of artemisinin in tetraploid plants has increased up to 56% compared to diploid plants. Alternatively, induced mutation using chemicals such as sodium azide (NaN3) and ethyl methane sulfonate (EMS) was effective in increasing the artemisinin biosynthesis in native plant (Al-Qurainy and Khan, 2010; Leow et al., 2020).

 Enhancing Glandular Trichomes

In some plant species, the production of some glandular type trichomes is enhanced by JA treatment (Chen et al., 2018) or UVB light (Yan et al., 2012). Indeed, the artemisinin content of A. annua is enhanced under the UV treatment at a dosage of 150 gray irradiation (Raymond et al., 2015) and UV-B radiation at 1.44 kJ m–2 d–1 (Pandey and Pandey-Rai, 2014) respectively. This could be due to both an effect on glandular trichome density and enhanced conversion of artemisinic aldehyde to artemisinin.

 Plant Growth Regulators

Various agricultural practices use plant growth regulators (PGRs) to improve artemisinin production. For example, the treatment of A. annua with Salicylic acid increases plant growth, leading to higher biomass (Aftab et al., 2010), altered plant morphology, artemisinin content and composition (Ma et al., 2009). Other studies have shown that PGR GA3 (Weathers et al., 2005; Zhang et al., 2005; Aftab et al., 2011) and JA can also increase the artemisinin content of A. annua (Zhou and Memelink, 2016). JA has been shown to boost artemisinin biosynthesis via the releasing of repressors of transcription factor TCP14-ORA at the promoters of double bond reductase 2 (DBR) and aldehyde dehydrogenase 1 (ADH1), two key genes in the artemisinin biosynthetic pathway (see Figure 3; Ma et al., 2018).

 Bioengineering of Artemisinin Production in <italic>Artemisia annua</italic>

Metabolic engineering may be used to improve the production of artemisinin in A. annua itself but is hampered by the difficulties in efficient transformation and regeneration of A. annua plants. Alternatively, the genes that have been isolated from A. annua that are involved in artemisinin production may be expressed in a heterologous host that is easier to transform and grow (Covello, 2008; Ma et al., 2015; Xie et al., 2016; Lv et al., 2017; Ikram et al., 2019). Options to manipulate artemisinin production in A. annua are briefly discussed below and summarized in Figure 5. The yield effects of the different transformation efforts of A. annua are summarized in Table 2.

Artemisia annua has been transformed with Agrobacterium genes that affect endogenous plant hormone levels (rol ABC or ipt), resulting in mild to up to 9 times higher artemisinin levels compared to untransformed (or empty vector transformed) control plants (Sa et al., 2001; Bulgakov, 2008; Dilshad et al., 2015; Kiani et al., 2016).

Other transformation strategies are aimed at boosting precursors, either by boosting flux through the Mevalonate pathway by ectopic expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) or by blocking unwanted side reactions that drain from the precursor pool (e.g., Squalene synthase (SQS), that diverts FPP to squalene) (Liao et al., 2016). Ectopic expression of HMGR in A. annua can boost artemisinin production (Aquil et al., 2009; Nafis et al., 2011; Ma et al., 2017), while also suppression of SQS can increase artemisinin levels (Paradise et al., 2008; Yang et al., 2008; Zhang et al., 2009; Table 2 and Figure 5).

Transformation approaches may also be aimed at boosting flux through the artemisinin biosynthetic pathway itself through overexpression of biosynthesis genes. Ectopic overexpression of farnesyl pyrophosphate synthase (FPS) alone or FPS with CYP71AV1 and CPR, increased artemisinin levels in transgenic plants (Table 2; Chen et al., 2000, 2013; Han et al., 2016; Banyai et al., 2010; Wani et al., 2021). In another study, upregulated expression of HMGR, FPS, ADS, Aldh1, and ADS in A. annua increased artemisinin level 39-56% fold (Lin et al., 2011; Figure 5).

The expression of endogenous biosynthesis genes may also be boosted by ectopic overexpression of relevant transcription factors (TF), provided expression of such TF is limiting for transcription of target genes. Multiple TFs (AP2/ERFs, WRKYs, bHLH, MYCs) have been identified in the regulation of endogenous artemisinin biosynthesis genes (Verpoorte and Memelink, 2002; Yang et al., 2012; Shen et al., 2016; Lv et al., 2017), but not all of these have been tested for stable transformation of A. annua. However, ectopic expression of WRKY does result in higher artemisinin production in A. annua (Jiang W. et al., 2016; Table 2 and Figure 5).

The capacity for extracellular accumulation of dihydroartemisinic acid for extra-cellular conversion to dihydroartemisinin may be of importance for the flux through the biosynthetic pathway to prevent feedback inhibition and possible toxic effects of pathway products. Studies in tobacco have shown that ABC-transporter AaPDR2, in concert with specific LTP AaTLP3 may be required for this function (Wang et al., 2016). In the tobacco assay, AaLTP3 and AaPDR2 prevent dihydroartemisinic acid reflux from the apoplast to the cell, resulting in higher artemisinin levels (Wang et al., 2016). However, manipulation of either ABC-transporter or LTP levels in A. annua has not been performed till now. Potentially, overexpression of these proteins could result in enhanced artemisinin production in A. annua (Figure 5).

Transformation approaches in Artemisia annua plants to boost artemisinin production. Ectopic overexpression of biosynthetic pathway genes (ADS, ALDH1, and DBR2), transcription factors (e.g., AP2/ERF, MYB, WRKY, and bHLH), and genes involved in extracellular sequestration of artemisinin (LTPs/PDRs) together with ectopic RNAi expression of competing pathways such squalene biosynthesis (SQS RNAi).

Introducing artemisinin (ART) pathway genes in Artemisia annua L. to improve the ART production using different strategies.

Expression type Yield References
Artemisia annua L. Overexpression of HMGR and ADS 1.73 mg/g DW Alam and Abdin (2011)
Artemisia annua L. Overexpression of CYP71AV1 and CPR 0.98 ± 0.18 mg/g Shen et al. (2012)
Artemisia annua L. Overexpression of FPS,CYP71AV1 and CPR 2.9 mg/g FW Chen et al. (2013)
Artemisia annua L. Overexpression of FPS 1.3% DW Banyai et al. (2010)
Artemisia annua L. Overexpression of HMGR 0.386 ± 0.0332mg/g DW Aquil et al. (2009)
Artemisia annua L. Suppressing the expression of SQS 31.4 mg/g DW Zhang et al. (2009)
Artemisia annua L. Overexpression of AaWRKY1 ≥ 14 4 mg/g DW Jiang W. et al. (2016)
Artemisia annua L. Overexpression of DBR2 1.5–2.14 mg/g DW Yuan et al. (2015)
Bioengineering of Artemisinin in Heterologous Production Platforms <italic>In planta</italic> Artemisinin Production

The genes for artemisinin production have also been expressed in other plants, either by transient expression or by stable transformation. To date, in planta artemisinin production has been reported for tobacco (Nicotiana benthamiana) and moss (Physcomitrella patens) (Table 3). Transient expression of genes in N. benthamiana leaves is used to characterize gene function and has the advantage that up to 15 genes may be co-expressed at the same time to transiently reconstitute entire biosynthetic pathways (Reed et al., 2017; Carqueijeiro et al., 2020). Reconstruction of the artemisinin biosynthetic pathway by transient co-expression of pathway genes (Wallaart et al., 2001; Zhang et al., 2011; Ting et al., 2013; Wang et al., 2016) or stable transformation with pathway genes (Farhi et al., 2011) resulted in the first ectopic production of artemisinin in another plant species (Table 3). Recently, the stable transformation of the moss (P. patens) with artemisinin pathway genes, demonstrated that this compound may also be produced in much more primitive plant species (Ikram et al., 2017; Table 3 and Figure 6). As a plant-based production platform of artemisinin, moss has been shown to have promiscuous substrate recognition which may be a substitute for some artemisinin biosynthetic pathway genes which are not present in for example N. benthamiana. Substrate promiscuity of sesquiterpenoids pathway from A. annua and Tanacetum parthenium for individual enzymes or pathways is previously reported (Beyraghdar Kashkooli et al., 2019). Besides, the simple purification step (due to lack of conjugation phenomenon) has been also stated as one of the advantages of this platform compared to the N. benthamiana.

Introducing artemisinin (ART) pathway genes in planta to improve the ART production using different strategies.

Expression type Yield References
Nicotiana benthamiana Transient expression of ART precursors’ genes 0.000220347 mg/g FW Ting et al. (2013)
Nicotiana benthamiana Expression of ADS 2e-7-1.7e-6mg/g FW Wallaart et al. (2001)
Nicotiana benthamiana Stable transformation of ADS 0.00048-0.00094 mg ART/g DW Farhi et al. (2011)
Nicotiana benthamiana Stable transformation of mtADS 0.005-0.0068 mg ART/g DW Farhi et al. (2011)
Nicotiana benthamiana Stable transformation of ADS, CYP71AV1, and DBR2 AD: > 0.004 mg/g FW; AA: > 0.0005 mg/g FW; DA: > 0.0015 mg/g FW Zhang et al. (2011)
Nicotiana benthamiana Transient expression of AaLTP3 and AaPDR2 0.003 mg/g DW Wang et al. (2016)
Nicotiana benthamiana SPG Transformation > 0.12 mg artemisinic acid/g biomass Fuentes et al. (2016)
Nicotiana benthamiana Stable transformation of ART B.P. genes 0.3–0.8 mg/g DW Malhotra et al. (2016)
Nicotiana benthamiana Transient expression of ART B.P. genes 0.0395 mg/g FW van Herpen et al. (2010)
Physcomitrella patens Stable transformation of ART B.P. genes 0.21 mg/g DW Ikram et al. (2017)

SPG, Stable Plastid Genome; FW, Fresh Weight; DW, Dry Weight; AD, Amorphadiene; AA, Artemisinic alcohol; DA, Dihydroartemisinic alcohol; ART B.P., Artemisinin biosynthetic pathway. All units are converted to milligram per gram (mg/g).

Heterologous overexpression of genes from artemisinin biosynthetic pathway in the host plants N. benthamiana and P. patens.

 Artemisinin Production in Yeast

Synthetic biology techniques play an important role in the exploration, overproduction, and structure diversification of phytochemicals (Qi et al., 2015; Muhammad et al., 2020; Alam et al., 2021). The full set of artemisinin biosynthesis genes have also been introduced into yeast, resulting in substantial production of dihydroartemisinic acid in fermenters (Immethun et al., 2013; Paddon et al., 2013; Tang et al., 2014; Table 4). This dihydroartemisinic acid can subsequently photo-chemically be converted to (dihydro)artemisinin (Paddon and Keasling, 2014). Some of the issues that play a role in the potential boosting of artemisinin production in A. annua as discussed above, also play a role in boosting artemisinin production in heterologous hosts. For instance, high activity of HMGR is also important for the ectopic production of artemisinin in yeast (Pitera et al., 2007; Ye and Bhatia, 2012; Tang et al., 2014) (Table 4).

De novo production of ART precursor via synthetic biology.

No. Host Gene(s) Yield References
1 Saccharomyces cerevisiae Amorpha-4,11-diene synthase Plasmid and genome-transformed produced 0.6 and 0.1 mg/l amorphadiene Lindahl et al. (2006)
2 Saccharomyces cerevisiae Mevalonate pathway, amorphadiene synthase, cytochrome P450 monooxygenase ≥ 100 mg/l artemisinic acid Ro et al. (2006)
3 Saccharomyces cerevisiae Amorphadiene synthase, amorphadiene oxidase, and cytochrome P450 reductase 250 mg/l (in shake-flask) and 1000 mg/l (in bioreactors) artemisinic acid Ro et al. (2008)
4 Saccharomyces cerevisiae Mevalonate pathway, overexpression of related genes > 40000 mg/l amorphadiene Westfall et al. (2012)
5 Saccharomyces cerevisiae Complete biosynthetic pathway 25000 mg/l artemisinic acid Paddon et al. (2013)
6 Escherichia coli Expression of a synthetic amorpha-4,11-diene synthase and the mevalonate isoprenoid pathway from Saccharomyces cerevisiae 24 mg caryophyllene equivalent/l amorphadiene Martin et al. (2003)
7 Escherichia coli Nine genes from mevalonate pathway 500 mg/l amorphadiene Newman et al. (2006)
8 Escherichia coli Overexpression of mevalonate pathway genes > 25000 mg/l amorphadiene Tsuruta et al. (2009)
9 Escherichia coli Amorphadiene biosynthetic pathway genes 293 mg/l/OD600 at 75h amorphadiene Anthony et al. (2009)
10 Escherichia coli Engineered substrate promiscuous P450BM3 250 mg/l amorphadiene Dietrich et al. (2009)
11 Escherichia coli Mevalonate pathway genes 235 mg/l amorphadiene Wu T. et al. (2011)

All units are converted to milligram per liter (mg/l).

 Conclusion

Whether artemisinin can be used to not only combat malaria, but also other diseases, including those acting on a pandemic scale, will very much depend on further validation of the efficacy of artemisinin in these other diseases and on how this compound can cost-effectively be made available to the community. Multiple and complementary approaches may be necessary to boost synthesis capacity, varying from the transformation of A. annua itself to boost artemisinin yield, to investment into heterologous production platforms that may be easier to scale up. At the same time, we should not ignore the lessons learned from monotherapy in combating disease, as this may result in the emergence of artemisinin-resistance, as currently happening for malaria. Therefore, both for malaria, as for the potential of artemisinin in combating COVID-19 and other viral infections ACTs or triple artemisinin-based combination therapies (TACTs) may be required to prevent the rise of artemisinin resistant disease variants.

 Author Contributions

ABK conceptualized the review. KF-K, AR, AB, ARK, and ABK wrote the manuscript. ABK, ARK, and AB reviewed the manuscript. KF-K, AR, and ABK did the figures visualization. All authors contributed to the article and approved the submitted version.

 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

We would like to thank Tarbiat Modares University.

 References Aftab T. Khan M. M. A. Idrees M. Naeem M. Moinuddin. (2011). Optimizing nitrogen levels combined with gibberellic acid for enhanced yield, photosynthetic attributes, enzyme activities, and artemisinin content of Artemisia annua. Front. Agric. China 5:51–59. 10.1007/s11703-011-1065-7 Aftab T. Masroor M. Khan A. Idrees M. Naeem M. Moinuddin. (2010). Salicylic acid acts as potent enhancer of growth, photosynthesis and artemisinin production in Artemisia annua L. J. Crop Sci. Biotechnol. 13 183–188. 10.1007/s12892-010-0040-3 Alam K. Hao J. Zhang Y. Li A. (2021). Synthetic biology-inspired strategies and tools for engineering of microbial natural product biosynthetic pathways. Biotechnol. Adv. 49:107759. 10.1016/j.biotechadv.2021.107759 33930523 Alam P. Abdin M. Z. (2011). Over-expression of HMG-CoA reductase and amorpha-4,11-diene synthase genes in Artemisia annua L. and its influence on artemisinin content. Plant Cell Rep. 30 1919–1928. 10.1007/s00299-011-1099-6 21655998 Alcântara D. D. F. Á Ribeiro H. F. Cardoso P. C. dos S. Araújo T. M. T. Burbano R. R. (2013). In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). J. Appl. Toxicol. 33 151–156. 10.1002/jat.1734 21953315 Aldieri E. Atragene D. Bergandi L. Riganti C. Costamagna C. Bosia A. (2003). Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett. 552 141–144. 10.1016/S0014-5793(03)00905-0 Al-Qurainy F. Khan S. (2010). Mutational approach for enhancement of artemisinin in Artemisia annua. J. Med. Plants Res. 4 1714–1726. 10.1016/j.jbiotec.2010.09.708 Anfosso L. Efferth T. Albini A. Pfeffer U. (2006). Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J. 6 269–278. 10.1038/sj.tpj.6500371 16432535 Anthony J. R. Anthony L. C. Nowroozi F. Kwon G. Newman J. D. Keasling J. D. (2009). Optimization of the mevalonate-based isoprenoid biosynthetic pathway in Escherichia coli for production of the anti-malarial drug precursor amorpha-4,11-diene. Metab. Eng. 11 13–19. 10.1016/j.ymben.2008.07.007 18775787 Antoine T. Fisher N. Amewu R. O’Neill P. M. Ward S. A. Biagini G. A. (2014). Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J. Antimicrob. Chemother. 69 1005–1016. 10.1093/jac/dkt486 24335485 Aquil S. Husaini A. M. Abdin M. Z. Rather G. M. (2009). Overexpression of the HMG-CoA reductase gene leads to enhanced artemisinin biosynthesis in transgenic Artemisia annua plants. Planta Med. 75 1453–1458. 10.1055/s-0029-1185775 19551613 Krishna S. Augustin Y. Wang J. Xu C. Staines H. M. Platteeuw H. (2021). Repurposing antimalarials to tackle the COVID-19 pandemic. Trends Parasitol. 37 8–11. 10.1016/j.pt.2020.10.00 Bahrami M. Kamalinejad M. Latifi S. A. Seif F. Dadmehr M. (2020). Cytokine storm in COVID-19 and parthenolide: preclinical evidence. Phyther. Res. 34 2429–2430. 10.1002/ptr.6776 32472655 Bailly C. Vergoten G. (2020). Glycyrrhizin: an alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol. Ther. 214:107618. 10.1016/j.pharmthera.2020.107618 32592716 Banyai W. Kirdmanee C. Mii M. Supaibulwatana K. (2010). Overexpression of farnesyl pyrophosphate synthase (FPS) gene affected artemisinin content and growth of Artemisia annua L. Plant Cell. Tissue Organ Cult. 103 255–265. 10.1007/s11240-010-9775-8 Beccafico S. Morozzi G. Marchetti M. C. Riccardi C. Sidoni A. Donato R. (2015). Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. Carcinogenesis 36 1071–1083. 10.1093/carcin/bgv098 26153023 Belhassan A. Zaki H. Chtita S. Alaqarbeh M. Alsakhen N. Benlyas M. (2021). Camphor, artemisinin and sumac phytochemicals as inhibitors against COVID-19: computational approach. Comput. Biol. Med. 136:104758. 10.1016/j.compbiomed.2021.104758 34411900 Berdelle N. Nikolova T. Quiros S. Efferth T. Kaina B. (2011). Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol. Cancer Ther. 10 2224–2233. 10.1158/1535-7163.MCT-11-0534 21998290 Bertea C. M. Freije J. R. Van Der Woude H. Verstappen F. W. A. Perk L. Marquez V. (2005). Identification of intermediates and enzymes involved in the early steps of artemisinin biosynthesis in Artemisia annua. Planta Med. 71 40–47. 10.1055/s-2005-837749 15678372 Beyraghdar Kashkooli A. van der Krol A. R. Bouwmeester H. (2018). “Terpenoid biosynthesis in plants,” in Flavour Sci., Verlag der Technischen Universität Graz, eds Siegmund B. Leitner E. 3–11. 10.3217/978-3-85125-593-5-1 32992130 Beyraghdar Kashkooli A. van der Krol A. R. Rabe P. Dickschat J. S. Bouwmeester H. (2019). Substrate promiscuity of enzymes from the sesquiterpene biosynthetic pathways from Artemisia annua and Tanacetum parthenium allows for novel combinatorial sesquiterpene production. Metab. Eng. 54 12–23. 10.1016/j.ymben.2019.01.007 30822491 Blazquez A. G. Fernandez-Dolon M. Sanchez-Vicente L. Maestre A. D. Gomez-San Miguel A. B. Alvarez M. (2013). Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorganic Med. Chem. 21 4432–4441. 10.1016/j.bmc.2013.04.059 23685181 Bridgford J. L. Xie S. C. Cobbold S. A. Pasaje C. F. A. Herrmann S. Yang T. (2018). Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat. Commun. 9 1–9. 10.1038/s41467-018-06221-1 30228310 Bulgakov V. P. (2008). Functions of rol genes in plant secondary metabolism. Biotechnol. Adv. 26 318–324. 10.1016/j.biotechadv.2008.03.001 18434069 Cao R. Hu H. Li Y. Wang X. Xu M. Liu J. (2020). Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect. Dis. 6 2524–2531. 10.1021/ACSINFECDIS.0C00522 32786284 Cao Y. Feng Y. H. Gao L. W. Li X. Y. Jin Q. X. Wang Y. Y. (2019). Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo. Int. Immunopharmacol. 70 110–116. 10.1016/j.intimp.2019.01.041 30798159 Carqueijeiro I. Langley C. Grzech D. Koudounas K. Papon N. O’Connor S. E. (2020). Beyond the semi-synthetic artemisinin: metabolic engineering of plant-derived anti-cancer drugs. Curr. Opin. Biotechnol. 65 17–24. 10.1016/j.copbio.2019.11.017 31841858 Chaijaroenkul W. Viyanant V. Mahavorasirikul W. Na-Bangchang K. (2011). Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. Asian Pacific J. Cancer Prev. 12 55–59. Charles D. J. Cebert E. Simon J. E. (1991). Characterization of the essential oil of Artemisia annua L. J. Essent. Oil Res. 3 33–39. 10.1080/10412905.1991.9697903 Chen C. Chen K. Feng Z. Wen X. Sun H. (2019). Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression. Acta Pharm. Sin. B 9 937–951. 10.1016/j.apsb.2019.05.001 31649844 Chen D. H. Ye H. C. Li G. F. (2000). Expression of a chimeric farnesyl diphosphate synthase gene in Artemisia annua L. transgenic plants via Agrobacterium tumefaciens-mediated transformation. Plant Sci. 155 179–185. 10.1016/S0168-9452(00)00217-X Chen G. Klinkhamer P. G. L. Escobar-Bravo R. Leiss K. A. (2018). Type VI glandular trichome density and their derived volatiles are differently induced by jasmonic acid in developing and fully developed tomato leaves: implications for thrips resistance. Plant Sci. 276 87–98. 10.1016/j.plantsci.2018.08.007 30348331 Chen H. Sun B. Pan S. Jiang H. Sun X. (2009). Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer. Drugs 20 131–140. 10.1097/CAD.0b013e3283212ade 19209030 Chen H. Sun B. Wang S. Pan S. Gao Y. Bai X. (2010). Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-κB. J. Cancer Res. Clin. Oncol. 136 897–903. 10.1007/s00432-009-0731-0 19941148 Chen H. H. Zhou H. J. Fang X. (2003). Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. 48 231–236. 10.1016/S1043-6618(03)00107-5 Chen K. Shou L. M. Lin F. Duan W. M. Wu M. Y. Xie X. (2014). Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anticancer. Drugs 25 652–662. 10.1097/CAD.0000000000000089 24518199 Chen X. Wong Y. K. Lim T. K. Lim W. H. Lin Q. Wang J. (2017). Artesunate activates the intrinsic apoptosis of HCT116 cells through the suppression of fatty acid synthesis and the NF-κB pathway. Molecules 22:1272. 10.3390/molecules22081272 28786914 Chen X. Zhang X. L. Zhang G. H. Gao Y. F. (2019). Artesunate promotes Th1 differentiation from CD4+ T cells to enhance cell apoptosis in ovarian cancer via miR-142. Brazilian J. Med. Biol. Res. 52 1–8. 10.1590/1414-431x20197992 31038546 Chen Y. Shen Q. Wang Y. Wang T. Wu S. Zhang L. (2013). The stacked over-expression of FPS, CYP71AV1 and CPR genes leads to the increase of artemisinin level in Artemisia annua L. Plant Biotechnol. Rep. 7 287–295. 10.1007/s11816-012-0262-z Cheong D. H. J. Tan D. W. S. Wong F. W. S. Tran T. (2020). Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases. Pharmacol. Res. 158:104901. 10.1016/j.phrs.2020.104901 32405226 Conti P. Younes A. (2020). Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J. Biol. Regul. Homeost. Agents 34 339–343. 10.23812/Editorial-Conti-3 32253888 Covello P. S. (2008). Making artemisinin. Phytochemistry 69 2881–2885. 10.1016/j.phytochem.2008.10.001 18977499 Cui C. Feng H. Shi X. Wang Y. Feng Z. Liu J. (2015). Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10. Int. Immunopharmacol. 27 110–121. 10.1016/j.intimp.2015.05.004 25978851 D’alessandro S. Scaccabarozzi D. Signorini L. Perego F. Ilboudo D. P. Ferrante P. (2020). The use of antimalarial drugs against viral infection. Microorganisms 8 1–26. 10.3390/microorganisms8010085 31936284 Davies M. J. Atkinson C. J. Burns C. Woolley J. G. Hipps N. A. Arroo R. R. J. (2009). Enhancement of artemisinin concentration and yield in response to optimization of nitrogen and potassium supply to Artemisia annua. Ann. Bot. 104 315–323. 10.1093/aob/mcp126 19483202 de Oliveira V. M. da Rocha M. N. Magalhães E. P. da Silva Mendes F. R. Marinho M. M. de Menezes R. R. P. P. B. (2021). Computational approach towards the design of artemisinin-thymoquinone hybrids against main protease of SARS-COV-2. Futur. J. Pharm. Sci. 7 1–20. 10.1186/s43094-021-00334-z 34514004 Dewick P. M. (2009). Medicinal Natural Products: A Biosynthetic Approach, 3rd Edn. New York, NY: Wiley. Dietrich J. A. Yoshikuni Y. Fisher K. J. Woolard F. X. Ockey D. McPhee D. J. (2009). A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450BM3. ACS Chem. Biol. 4 261–267. 10.1021/cb900006h 19271725 Dilshad E. Cusido R. M. Palazon J. Estrada K. R. Bonfill M. Mirza B. (2015). Enhanced artemisinin yield by expression of rol genes in Artemisia annua. Malar. J. 14 1–10. 10.1186/s12936-015-0951-5 26510528 Disbrow G. L. Baege A. C. Kierpiec K. A. Yuan H. Centeno J. A. Thibodeaux C. A. (2005). Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res. 65 10854–10861. 10.1158/0008-5472.CAN-05-1216 16322232 Dong F. Zhou X. Li C. Yan S. Deng X. Cao Z. (2014). Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis. Cancer Biol. Ther. 15 1479–1488. 10.4161/15384047.2014.955728 25482945 Dong H. Y. Wang Z. F. (2014). Antitumor effects of artesunate on human breast carcinoma MCF-7 cells and IGF-IR expression in nude mice xenografts. Chin. J. Cancer Res. 26 200–207. 10.3978/j.issn.1000-9604.2014.04.07 24826061 Dong L. Hu S. Gao J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 14 58–60. 10.5582/ddt.2020.01012 32147628 Du J. H. Zhang H. De Ma Z. J. Ji K. M. (2010). Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother. Pharmacol. 65 895–902. 10.1007/s00280-009-1095-5 19690861 Dwivedi A. Mazumder A. du Plessis L. du Preez J. L. Haynes R. K. du Plessis J. (2015). In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomed. Nanotechnol. Biol. Med. 11 2041–2050. 10.1016/j.nano.2015.07.010 26282380 Efferth T. (2018). Beyond malaria: the inhibition of viruses by artemisinin-type compounds. Biotechnol. Adv. 36 1730–1737. 10.1016/j.biotechadv.2018.01.001 29305894 Efferth T. Benakis A. Romero M. R. Tomicic M. Rauh R. Steinbach D. (2004). Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med. 37 998–1009. 10.1016/j.freeradbiomed.2004.06.023 15336316 Efferth T. Marschall M. Wang X. Huong S.-M. Hauber I. Olbrich A. (2002). Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol. Med. 80 233–242. 10.1007/s00109-001-0300-8 11976732 Efferth T. Oesch F. (2021). The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases. Med. Res. Rev. 41 3023–3061. 10.1002/med.21842 34288018 Efferth T. Romero M. R. Wolf D. G. Stamminger T. Marin J. J. G. Marschall M. (2008). The antiviral activities of artemisinin and artesunate. Clin. Infect. Dis. 47 804–811. 10.1086/591195 18699744 Eling N. Reuter L. Hazin J. Hamacher-Brady A. Brady N. R. (2015). Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2 517–532. 10.18632/oncoscience.160 26097885 Farhi M. Marhevka E. Ben-Ari J. Algamas-Dimantov A. Liang Z. Zeevi V. (2011). Generation of the potent anti-malarial drug artemisinin in tobacco. Nat. Biotechnol. 29 1072–1074. 10.1038/nbt.2054 22158354 Fei Z. Gu W. Xie R. Su H. Jiang Y. (2018). Artesunate enhances radiosensitivity of esophageal cancer cells by inhibiting the repair of DNA damage. J. Pharmacol. Sci. 138 131–137. 10.1016/j.jphs.2018.09.011 30337244 Ferreira J. F. S. Laughlin J. C. Delabays N. de Magalhães P. M. (2005). Cultivation and genetics of Artemisia annua L. for increased production of the antimalarial artemisinin. Plant Genet. Resour. 3 206–229. 10.1079/pgr200585 Firestone T. M. Oyewole O. O. Reid S. P. Ng C. L. (2021). Repurposing quinoline and artemisinin antimalarials as therapeutics for SARS-CoV-2: rationale and implications. ACS Pharmacol. Transl. Sci. 4 613–623. 10.1021/acsptsci.0c00222 33855275 Fröhlich T. Kiss A. Wölfling J. Mernyák E. Kulmány ÁE. Minorics R. (2018). Synthesis of artemisinin-estrogen hybrids highly active against HCMV, P. falciparum, and cervical and breast Cancer. ACS Med. Chem. Lett. 9 1128–1133. 10.1021/acsmedchemlett.8b00381 30429957 Fröhlich T. Ndreshkjana B. Muenzner J. K. Reiter C. Hofmeister E. Mederer S. (2017). Synthesis of novel hybrids of thymoquinone and artemisinin with hig activity and selectivity against colon cancer. Chem. Med. Chem. 12 226–234. 10.1002/cmdc.201600594 27973725 Fuentes P. Zhou F. Erban A. Karcher D. Kopka J. Bock R. (2016). A new synthetic biology approach allows transfer of an entire metabolic pathway from a medicinal plant to a biomass crop. Elife 5 1–26. 10.7554/eLife.13664 27296645 Fuzimoto A. D. (2021). An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment. J. Integr. Med. 19 375–388. 10.1016/j.joim.2021.07.003 34479848 Gendrot M. Duflot I. Boxberger M. Delandre O. Jardot P. Le Bideau M. (2020). Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: in vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int. J. Infect. Dis. 99 437–440. 10.1016/j.ijid.2020.08.032 32805422 Gong Y. Gallis B. M. Goodlett D. R. Yang Y. Lu H. Lacoste E. (2013). Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines. Anticancer Res. 33 123–132. Graham L. A. Besser K. Blumer S. Branigan C. A. Czechowski T. Elias L. (2010). The genetic map of Artemisia annua L identifies loci affecting yield of the antimalarial drug artemisinin. Science 327 328–331. 10.1126/science.1182612 20075252 Gravett A. M. Liu W. M. Krishna S. Chan W. C. Haynes R. K. Wilson N. L. (2011). In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother. Pharmacol. 67 569–577. 10.1007/s00280-010-1355-4 20490800 Greenshields A. L. Shepherd T. G. Hoskin D. W. (2017). Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol. Carcinog 56 75–93. 10.1002/mc.22474 26878598 Gu Y. Wang X. Wang X. Yuan M. Wu G. Hu J. (2012). Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-κB pathway. Tohoku J. Exp. Med. 227 161–170. 10.1620/tjem.227.161 22729178 Guastalegname M. Vallone A. (2020). Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin. Infect. Dis. 71 888–889. 10.1093/cid/ciaa321 32211771 Hamacher-Brady A. Stein H. A. Turschner S. Toegel I. Mora R. Jennewein N. (2011). Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J. Biol. Chem. 286 6587–6601. 10.1074/jbc.M110.210047 21149439 Han J. Wang H. Kanagarajan S. Hao M. Lundgren A. Brodelius P. E. (2016). Promoting artemisinin biosynthesis in Artemisia annua plants by substrate channeling. Mol. Plant 9 946–948. 10.1016/j.molp.2016.03.004 26995295 Hao D. L. Xie R. De G. J. Yi H. Zang C. Yang M. Y. (2020). PH-responsive artesunate polymer prodrugs with enhanced ablation effect on rodent xenograft colon cancer. Int. J. Nanomedicine 15 1771–1786. 10.2147/IJN.S242032 32214810 Hassanipour S. Arab-Zozani M. Amani B. Heidarzad F. Fathalipour M. Martinez-de-Hoyo R. (2021). The efficacy and safety of favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci. Rep. 11 1–11. 10.1038/s41598-021-90551-6 34040117 Heymann D. L. Shindo N. (2020). COVID-19: what is next for public health? Lancet 395 542–545. 10.1016/S0140-6736(20)30374-3 34003294 Hu W. Chen S. S. Zhang J. L. Lou X. E. Zhou H. J. (2014). Dihydroartemisinin induces autophagy by suppressing NF-κB activation. Cancer Lett. 343 239–248. 10.1016/j.canlet.2013.09.035 24099910 Hu Y. Liu M. Qin H. Lin H. An X. Shi Z. (2021). Artemether, artesunate, arteannuin B, echinatin, licochalcone B and andrographolide effectively inhibit SARS-CoV-2 and related viruses in vitro. Front. Cell Infect. Microbiol. 11:1–8. 10.3389/fcimb.2021.680127 34527599 Huang J. Tao G. Liu J. Cai J. Huang Z. Chen J. X. (2020). Current prevention of COVID-19: natural products and herbal medicine. Front. Pharmacol. 11:1–18. 10.3389/fphar.2020.588508 33178026 Hwang Y. P. Yun H. J. Kim H. G. Han E. H. Lee G. W. Jeong H. G. (2010). Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCα/Raf/MAPKs and NF-κB/AP-1-dependent mechanisms. Biochem. Pharmacol. 79 1714–1726. 10.1016/j.bcp.2010.02.003 20152819 Iannicelli J. Guariniello J. Tossi V. E. Regalado J. J. Di Ciaccio L. van Baren C. M. (2020). The “polyploid effect” in the breeding of aromatic and medicinal species. Sci. Hortic. 260:108854. 10.1016/j.scienta.2019.108854 Ikram N. K. Beyraghdar Kashkooli A. Peramuna A. van der Krol A. R. Bouwmeester H. Simonsen H. T. (2019). Insights into heterologous biosynthesis of arteannuin B and artemisinin in physcomitrella patens. Molecules 24:822. 10.3390/molecules24213822 31652784 Ikram N. K. B. K. Beyraghdar Kashkooli A. Peramuna A. V. van der Krol A. R. Bouwmeester H. Simonsen H. T. (2017). Stable production of the antimalarial drug artemisinin in the moss physcomitrella patens. Front. Bioeng. Biotechnol. 5:1–8. 10.3389/fbioe.2017.00047 28861412 Ikram N. K. B. K. Simonsen H. T. (2017). A review of biotechnological artemisinin production in plants. Front. Plant Sci. 8:1–10. 10.3389/fpls.2017.01966 29187859 Ilamathi M. Prabu P. C. Ayyappa K. A. Sivaramakrishnan V. (2016). Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling. Biomed. Pharmacother. 82 72–79. 10.1016/j.biopha.2016.04.061 27470341 Immethun C. M. Hoynes-O’Connor A. G. Balassy A. Moon T. S. (2013). Microbial production of isoprenoids enabled by synthetic biology. Front. Microbiol. 4:1–8. 10.3389/fmicb.2013.00075 23577007 Ishikawa C. Senba M. Mori N. (2020). Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. Eur. J. Pharmacol. 872:172953. 10.1016/j.ejphar.2020.172953 31996318 Jamalzadeh L. Ghafoori H. Aghamaali M. Sariri R. (2017). Induction of apoptosis in human breast cancer MCF-7 cells by a semi- synthetic derivative of artemisinin: a caspase-related mechanism. Iran. J. Biotechnol. 15 157–165. 10.15171/ijb.1567 29845064 Javed H. Meeran M. F. N. Jha N. K. Ojha S. (2021). Carvacrol, a plant metabolite targeting viral protease (Mpro) and ACE2 in host cells can be a possible candidate for COVID-19. Front. Plant Sci. 11:1–10. 10.3389/fpls.2020.601335 33664752 Jelodar N. B. Bhatt A. Mohamed K. Keng C. L. (2014). New cultivation approaches of Artemisia annua L. for a sustainable production of the antimalarial drug artemisinin. J. Med. Plants Res. 8 441–447. 10.5897/JMPR11.1053 Jha P. Ram M. Khan M. A. Kiran U. Abdin M. Z. (2011). Impact of organic manure and chemical fertilizers on artemisinin content and yield in Artemisia annua L. Int. Crop. Prod. 33 296–301. 10.1016/j.indcrop.2010.12.011 Jiang F. Zhou J. Y. Zhang D. Liu M. H. Chen Y. G. (2018). Artesunate induces apoptosis and autophagy in HCT116 colon cancer cells, and autophagy inhibition enhances the artesunate-induced apoptosis. Int. J. Mol. Med. 42 1295–1304. 10.3892/ijmm.2018.3712 29901098 Jiang J. Geng G. Yu X. Liu H. Gao J. An H. (2016). Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis. Oncotarget 7 87271–87283. 10.18632/oncotarget.13536 27895313 Jiang W. Fu X. Pan Q. Tang Y. Shen Q. Lv Z. (2016). Overexpression of AaWRKY1 leads to an enhanced content of artemisinin in Artemisia annua. Biomed Res. Int. 2016:971. 10.1155/2016/7314971 27064403 Jiang W. Huang Y. Wang J. P. Yu X. Y. Zhang L. Y. (2013). The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo. Asian Pacific J. Cancer Prev. 14 4615–4619. 10.7314/APJCP.2013.14.8.4615 24083713 Jiang Z. Chai J. Chuang H. H. F. Li S. Wang T. Cheng Y. (2012). Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. Anticancer. Drugs 23 606–613. 10.1097/CAD.0b013e328350e8ac 22421370 Jiao Y. Ge C. M. Meng Q. H. Cao J. P. Tong J. Fan S. J. (2007). Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol. Sin. 28 1045–1056. 10.1111/j.1745-7254.2007.00612.x 17588342 Judd R. Bagley M. C. Li M. Zhu Y. Lei C. Yuzuak S. (2019). Artemisinin biosynthesis in non-glandular trichome cells of Artemisia annua. Mol. Plant 12 704–714. 10.1016/j.molp.2019.02.011 30851440 Kapepula P. M. Kabengele J. K. Kingombe M. van Bambeke F. Tulkens P. M. Kishabongo A. S. (2020). Artemisia spp. derivatives for COVID-19 treatment: anecdotal use, political hype, treatment potential, challenges, and road map to randomized clinical trials. Am. J. Trop. Med. Hyg. 103 960–964. 10.4269/ajtmh.20-0820 32705976 Kiani B. H. Suberu J. Mirza B. (2016). Cellular engineering of Artemisia annua and Artemisia dubia with the rol ABC genes for enhanced production of potent anti-malarial drug artemisinin. Malar. J. 15 1–17. 10.1186/s12936-016-1312-8 27142388 Klayman D. L. (1985). Qinghaosu (artemisinin): an antimalarial drug from china. Published by: American. Science 228 1049–1055. Koi H. Takahashi N. Fuchi Y. Umeno T. Muramatsu Y. Seimiya H. (2020). A fully synthetic 6-aza-artemisinin bearing an amphiphilic chain generates aggregates and exhibits anti-cancer activities. Org. Biomol. Chem. 18 5339–5343. 10.1039/d0ob00919a 32618320 Koshak D. A. E. Koshak P. E. A. (2020). Nigella sativa L as a potential phytotherapy for coronavirus disease 2019: a mini review of in silico studies. Curr. Ther. Res. 93:100602. 10.1016/j.curtheres.2020.100602 32863400 Krishna S. Ganapathi S. Ster I. C. Saeed M. E. M. Cowan M. Finlayson C. (2015). A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine 2 82–90. 10.1016/j.ebiom.2014.11.010 26137537 Kshirsagar S. G. Rao R. V. (2021). Antiviral and immunomodulation effects of Artemisia. Medicine 57 1–12. 10.3390/medicina57030217 33673527 Kumar V. L. Verma S. Das P. (2019). Artesunate suppresses inflammation and oxidative stress in a rat model of colorectal cancer. Drug Dev. Res. 80 1089–1097. 10.1002/ddr.21590 31471932 Lai C. C. Shih T. P. Ko W. C. Tang H. J. Hsueh P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents 55:105924. 10.1016/j.ijantimicag.2020.105924 32081636 Lai H. Nakase I. Lacoste E. Singh N. P. Sasaki T. (2009). Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res. 29 3807–3810. Lai H. Sasaki T. Singh N. P. Messay A. (2005). Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 76 1267–1279. 10.1016/j.lfs.2004.08.020 15642597 Lai H. Singh N. P. (2006). Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett. 231 43–48. 10.1016/j.canlet.2005.01.019 16356830 Lai L. Chen Y. Tian X. Li X. Zhang X. Lei J. (2015). Artesunate alleviates hepatic fibrosis induced by multiple pathogenic factors and inflammation through the inhibition of LPS/TLR4/NF-κB signaling pathway in rats. Eur. J. Pharmacol. 765 234–241. 10.1016/j.ejphar.2015.08.040 26318197 Langroudi L. Hassan Z. M. Ebtekar M. Mahdavi M. Pakravan N. Noori S. (2010). A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. Int. Immunopharmacol. 10 1055–1061. 10.1016/j.intimp.2010.06.005 20601187 Larson S. A. Dolivo D. M. Dominko T. (2019). Artesunate inhibits myofibroblast formation via induction of apoptosis and antagonism of pro-fibrotic gene expression in human dermal fibroblasts. Cell Biol. Int. 43 1317–1322. 10.1002/cbin.11220 31441159 Lei C. Ma D. Pu G. Qiu X. Du Z. Wang H. (2011). Foliar application of chitosan activates artemisinin biosynthesis in artemisia. Int. Crop. Prod. 33 176–182. 10.1016/j.indcrop.2010.10.001 Leow E. S. Jelodar N. B. Chan L. K. (2020). Ethyl methane sulfonate (Ems) enhanced the formation of leaf glandular trichomes and the production of artemisinin in Artemisia annua L. Asia Pacific J. Sci. Technol. 25 1–9. Li B. Bu S. Sun J. Guo Y. Lai D. (2018). Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. Acta Biochim. Biophys. Sin. 50 1227–1235. 10.1093/abbs/gmy125 30395153 Li G. Yuan M. Li H. Deng C. Wang Q. Tang Y. (2020). Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Int. J. Antimicrob. Agents 57:106216. 10.1016/j.ijantimicag.2020.106216 33152450 Li H. Xu K. Pian G. Sun S. (2019). Artesunate and sorafenib: combinatorial inhibition of liver cancer cell growth. Oncol. Lett. 18 4735–4743. 10.3892/ol.2019.10810 31611983 Li J. Feng W. Lu H. Wei Y. Ma S. Wei L. (2019). Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation. J. Cell. Physiol. 234 12663–12675. 10.1002/jcp.27875 30536376 Li L. N. Zhang H. D. Yuan S. J. Tian Z. Y. Wang L. Sun Z. X. (2007). Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/β-catenin pathway. Int. J. Cancer 121 1360–1365. 10.1002/ijc.22804 17520675 Li L. N. Zhang H. D. Yuan S. J. Yang D. X. Wang L. Sun Z. X. (2008). Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur. J. Pharmacol. 588 1–8. 10.1016/j.ejphar.2008.03.041 18448095 Li W. Ma G. Deng Y. Wu Q. Wang Z. Zhou Q. (2021). Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhibiting MAPK pathway. Gene 766:145134. 10.1016/j.gene.2020.145134 32898605 Li X. Ba Q. Liu Y. Yue Q. Chen P. Li J. (2017). Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRá protein. Cell. Discov. 3 1–13. 10.1038/celldisc.2017.42 29387451 Li X. Gu S. Sun D. Dai H. Chen H. Zhang Z. (2018). The selectivity of artemisinin-based drugs on human lung normal and cancer cells. Environ. Toxicol. Pharmacol. 57 86–94. 10.1016/j.etap.2017.12.004 29227908 Li Y. Sui H. Jiang C. Li S. Han Y. Huang P. (2018). Dihydroartemisinin increases the sensitivity of photodynamic therapy via NF-κB/HIF-1α/VEGF pathway in esophageal cancer cell in vitro and in vivo. Cell Physiol. Biochem. 48 2035–2045. 10.1159/000492541 30099443 Li Y. J. Zhou J. H. Du X. X. Jia D. X. Wu C. L. Huang P. (2014). Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cells. Cell Physiol. Biochem. 33 1527–1536. 10.1159/000358716 24854841 Liang W. Liu J. Wu H. Qiao X. Lu X. Liu Y. (2019). Artemisinin induced reversal of EMT affects the molecular biological activity of ovarian cancer SKOV3 cell lines. Oncol. Lett. 18 3407–3414. 10.3892/ol.2019.10608 31452821 Liao P. Hemmerlin A. Bach T. J. Chye M. (2016). The potential of the mevalonate pathway for enhanced isoprenoid production. Biotechnol. Adv. 34 697–713. 10.1016/j.biotechadv.2016.03.005 26995109 Lin X. Zhou Y. Zhang J. Lu X. Zhang F. Shen Q. (2011). Enhancement of artemisinin content in tetraploid Artemisia annua plants by modulating the expression of genes in artemisinin biosynthetic pathway. Biotechnol. Appl. Biochem. 58 50–57. 10.1002/bab.13 21446959 Lindahl A. L. Olsson M. E. Mercke P. Tollbom Ö Schelin J. Brodelius M. (2006). Production of the artemisinin precursor amorpha-4,11-diene by engineered Saccharomyces cerevisiae. Biotechnol. Lett. 28 571–580. 10.1007/s10529-006-0015-6 16614895 Liu B. Wang H. Du Z. Li G. Ye H. (2011). Metabolic engineering of artemisinin biosynthesis in Artemisia annua L. Plant Cell Rep. 30 689–694. 10.1007/s00299-010-0967-9 21184232 Liu C. Xu Y. W. X. Ouyang F. Ye H. Li G. (1999). Improvement of artemisinin accumulation in hairy root cultures of Artemisia annua L by fungal elicitor. Bioproc. Eng. 20 161–164. 10.1007/PL00009041 Liu T. Zhang J. Yang Y. Ma H. Li Z. Zhang J. (2020). The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol. Med. 12:e12421. 10.15252/emmm.202012421 32428990 Liu T. Zhang L. Joo D. Sun S. C. (2017). NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2:23. 10.1038/sigtrans.2017.23 29158945 Liu Y. Gao S. Zhu J. Zheng Y. Zhang H. Sun H. (2018). Dihydroartemisinin induces apoptosis and inhibits proliferation, migration, and invasion in epithelial ovarian cancer via inhibition of the hedgehog signaling pathway. Cancer Med. 7 5704–5715. 10.1002/cam4.1827 30338663 Lu J. J. Chen S. M. Zhang X. W. Ding J. Meng L. H. (2011). The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest. New Drugs 29 1276–1283. 10.1007/s10637-010-9481-8 20607588 Lu R. Zhao X. Li J. Niu P. Yang B. Wu H. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395 565–574. 10.1016/S0140-6736(20)30251-8 34003294 Luo J. Zhu W. Tang Y. Cao H. Zhou Y. Ji R. (2014). Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. Radiat. Oncol. 9 1–12. 10.1186/1748-717X-9-84 24666614 Lv Z. Zhang L. Tang K. (2017). New insights into artemisinin regulation. Plant Signal. Behav. 12:1366398. 10.1080/15592324.2017.1366398 28837410 Lyu M. Fan G. Xiao G. Wang T. Xu D. Gao J. (2021). Traditional chinese medicine in COVID-19. Acta Pharm. Sin. B 11 3337–3363. 10.1016/j.apsb.2021.09.008 34567957 Ma D. Li G. Alejos-Gonzalez F. Zhu Y. Xue Z. Wang A. (2017). Overexpression of a type-I isopentenyl pyrophosphate isomerase of Artemisia annua in the cytosol leads to high arteannuin B production and artemisinin increase. Plant J. 91 466–479. 10.1111/tpj.13583 28440881 Ma D. Pu G. Lei C. Ma L. Wang H. Guo Y. (2009). Isolation and characterization of AaWRKY1, an Artemisia annua transcription factor that regulates the amorpha-4,11-diene synthase gene, a key gene of artemisinin biosynthesis. Plant Cell Physiol. 50 2146–2161. 10.1093/pcp/pcp149 19880398 Ma D. M. Wang Z. Wang L. Alejos-Gonzales F. Sun M. A. Xie D. Y. (2015). A genome-wide scenario of terpene pathways in self-pollinated Artemisia annua. Mol. Plant 8 1580–1598. 10.1016/j.molp.2015.07.004 26192869 Ma H. Yao Q. Zhang A. M. Lin S. Wang X. X. Wu L. (2011). The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model. Molecules 16 10556–10569. 10.3390/molecules161210556 22183882 Ma Y.-N. Xu D.-B. Li L. Zhang F. Fu X.-Q. Shen Q. (2018). Jasmonate promotes artemisinin biosynthesis by activating the TCP14-ORA complex in Artemisia annua. Sci. Adv. 4:eaas9357. 10.1126/sciadv.aas9357 30627665 Malhotra K. Subramaniyan M. Rawat K. Kalamuddin M. Qureshi M. I. Malhotra P. (2016). Compartmentalized metabolic engineering for artemisinin biosynthesis and effective malaria treatment by oral delivery of plant cells. Mol. Plant 9 1464–1477. 10.1016/j.molp.2016.09.013 27773616 Mandal S. Upadhyay S. Wajid S. Ram M. Jain D. C. Singh V. P. (2014). Arbuscular mycorrhiza increase artemisinin accumulation in Artemisia annua by higher expression of key biosynthesis genes via enhanced jasmonic acid levels. Mycorrhiza 25:25366131. 10.1007/s00572-014-0614-3 25366131 Mani J. S. Johnson J. B. Steel J. C. Broszczak D. A. Neilsen P. M. Walsh K. B. (2020). Natural product-derived phytochemicals as potential agents against coronaviruses: a review. Virus Res. 284:197989. 10.1016/j.virusres.2020.197989 32360300 Mao H. Gu H. Qu X. Sun J. Song B. Gao W. (2013). Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro. Int. J. Mol. Med. 31 213–218. 10.3892/ijmm.2012.1176 23138847 Martin V. J. J. Pitera D. J. Withers S. T. Newman J. D. Keasling J. D. (2003). Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nat. Biotechnol. 21 796–802. 10.1038/nbt833 12778056 Mbengue A. Bhattacharjee S. Pandharkar T. Liu H. Estiu G. Stahelin R. V. (2015). A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520 683–687. 10.1038/nature14412 25874676 McDowell A. Hill K. S. McCorkle J. R. Gorski J. Zhang Y. Salahudeen A. A. (2021). Preclinical evaluation of artesunate as an antineoplastic agent in ovarian cancer treatment. Diagnostics 11:395. 10.3390/diagnostics11030395 33652561 Mehta P. McAuley D. F. Brown M. Sanchez E. Tattersall R. S. Manson J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395 1033–1034. 10.1016/S0140-6736(20)30628-0 34003294 Mercke P. Bengtsson M. Bouwmeester H. J. Posthumus M. A. Brodelius P. E. (2000). Molecular cloning, expression, and characterization of amorpha-4,11-diene synthase, a key enzyme of artemisinin biosynthesis in Artemisia annua L. Arch. Biochem. Biophys. 381 173–180. 10.1006/abbi.2000.1962 11032404 Mert A. K1r1c1 S. Ayanoğlu F. (2002). The effects of different plant densities on yield, yield components and quality of Artemisia annua L. ecotypes. J. Herbs. Spices Med. Plants 9 413–418. 10.1300/J044v09n04_20 Michaelis M. Kleinschmidt M. C. Barth S. Rothweiler F. Geiler J. Breitling R. (2010). Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem. Pharmacol. 79 130–136. 10.1016/j.bcp.2009.08.013 19698702 Mok S. Ashley E. A. Ferreira P. E. Zhu L. Lin Z. Yeo T. (2015). Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347 431–435. 10.1126/science.1260403 25502316 Mondal A. Chatterji U. (2015). Artemisinin represses telomerase subunits and induces apoptosis in HPV-39 Infected human cervical cancer cells. J. Cell. Biochem. 116 1968–1981. 10.1002/jcb.25152 25755006 Muhammad A. Feng X. Rasool A. Sun W. Li C. (2020). Production of plant natural products through engineered Yarrowia lipolytica. Biotechnol. Adv. 43:107555. 10.1016/j.biotechadv.2020.107555 32422161 Nafis T. Akmal M. Ram M. Alam P. Ahlawat S. Mohd A. (2011). Enhancement of artemisinin content by constitutive expression of the HMG-CoA reductase gene in high-yielding strain of Artemisia annua L. Plant Biotechnol. Rep. 5 53–60. 10.1007/s11816-010-0156-x Nair M. S. Huang Y. Fidock D. A. Towler M. J. Weathers P. J. (2022). Artemisia annua L. hot-water extracts show potent activity in vitro against Covid-19 variants including delta. J. Ethnopharmacol. 284:114797. 10.1016/j.jep.2021.114797 34737005 Nakase I. Gallis B. Takatani-Nakase T. Oh S. Lacoste E. Singh N. P. (2009). Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett. 274 290–298. 10.1016/j.canlet.2008.09.023 19006645 Nazrul Islam M. Hossain K. S. Sarker P. P. Ferdous J. Hannan M. A. Rahman M. M. (2021). Revisiting pharmacological potentials of Nigella sativa seed: a promising option for COVID-19 prevention and cure. Phyther. Res. 35 1329–1344. 10.1002/ptr.6895 33047412 Newman J. D. Marshall J. Chang M. Nowroozi F. Paradise E. Pitera D. (2006). High-level production of amorpha-4,11-diene in a two-phase partitioning bioreactor of metabolically engineered Escherichia coli. Biotechnol. Bioeng. 95 684–691. 10.1002/bit.21017 16878333 Nie C. Trimpert J. Moon S. Haag R. Gilmore K. Kaufer B. B. (2021). In vitro efficacy of artemisia extracts against SARS-CoV-2. Virol. J. 18 1–7. 10.1186/s12985-021-01651-8 34496903 Nunes J. J. Pandey S. K. Yadav A. Goel S. Ateeq B. (2017). Targeting NF-kappa B signaling by artesunate restores sensitivity of castrate-resistant prostate cancer cells to antiandrogens. Neoplasia 19 333–345. 10.1016/j.neo.2017.02.002 28319807 Ohgami Y. Elstad C. A. Chung E. Shirachi D. Y. Quock R. M. Lai H. C. (2010). Effect of hyperbaric oxygen on the anticancer effect of artemisinin on molt-4 human leukemia cells. Anticancer Res. 30 4467–4470. O’Neill P. M. Barton V. E. Ward S. A. (2010). The molecular mechanism of action of artemisinin-the debate continues. Molecules 15 1705–1721. 10.3390/molecules15031705 20336009 Ooko E. Saeed M. E. M. Kadioglu O. Sarvi S. Colak M. Elmasaoudi K. (2015). Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 22 1045–1054. 10.1016/j.phymed.2015.08.002 26407947 Orege J. I. Adeyemi S. B. Tiamiyu B. B. Akinyemi T. O. Ibrahim Y. A. Orege O. B. (2021). Artemisia and artemisia-based products for COVID-19 management: current state and future perspective. Adv. Tradit. Med. 5 1–12. 10.1007/s13596-021-00576-5 Osaki T. Uto Y. Ishizuka M. Tanaka T. Yamanaka N. Kurahashi T. (2017). Artesunate enhances the cytotoxicity of 5-aminolevulinic acid-based sonodynamic therapy against mouse mammary tumor cells in vitro. Molecules 22:533. 10.3390/molecules22040533 28346389 Paddon C. J. Keasling J. D. (2014). Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat. Rev. Microbiol. 12 355–367. 10.1038/nrmicro3240 24686413 Paddon C. J. Westfall P. J. Pitera D. J. Benjamin K. Fisher K. McPhee D. (2013). High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496 528–532. 10.1038/nature12051 23575629 Pahl H. L. (1999). Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18 6853–6866. 10.1038/sj.onc.1203239 10602461 Pandey N. Pandey-Rai S. (2014). Short term UV-B radiation-mediated transcriptional responses and altered secondary metabolism of in vitro propagated plantlets of Artemisia annua L. Plant Cell, Tissue Organ Cult. 116 371–385. 10.1007/s11240-013-0413-0 Paradise E. M. Kirby J. Chan R. Keasling J. D. (2008). Redirection of flux through the FPP branch-point in Saccharomyces cerevisiae by down-regulating squalene synthase. Biotechnol. Bioeng. 100 371–378. 10.1002/bit.21766 18175359 Parshikov I. A. Netrusov A. I. Sutherland J. B. (2012). Microbial transformation of antimalarial terpenoids. Biotechnol. Adv. 30 1516–1523. 10.1016/j.biotechadv.2012.03.010 22484051 Pirali M. Taheri M. Zarei S. Majidi M. Ghafouri H. (2020). Artesunate, as a HSP70 ATPase activity inhibitor, induces apoptosis in breast cancer cells. Int. J. Biol. Macromol. 164 3369–3375. 10.1016/j.ijbiomac.2020.08.198 32861782 Pitera D. J. Paddon C. J. Newman J. D. Keasling J. D. (2007). Balancing a heterologous mevalonate pathway for improved isoprenoid production in Escherichia coli. Metab. Eng. 9 193–207. 10.1016/j.ymben.2006.11.002 17239639 Qi H. Li B. Zhang W. Liu D. Yuan Y. (2015). Modularization of genetic elements promotes synthetic metabolic engineering. Biotechnol. Adv. 33 1412–1419. 10.1016/j.biotechadv.2015.04.002 25868805 Rasheed S. A. K. Efferth T. Asangani I. A. Allgayer H. (2010). First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int. J. Cancer 127 1475–1485. 10.1002/ijc.25315 20232396 Raymond M. Miriam K. Oliver K. Edwin M. Stephen K. (2015). Enhancement of artemisinin in Artemisia annua L. through induced mutation. OALib 02 1–11. 10.4236/oalib.1102189 Raza A. Ghoshal A. Chockalingam S. Ghosh S. S. (2017). Connexin-43 enhances tumor suppressing activity of artesunate via gap junction-dependent as well as independent pathways in human breast cancer cells. Sci. Rep. 7 1–13. 10.1038/s41598-017-08058-y 28790385 Reed J. Stephenson M. J. Miettinen K. Brouwer B. Leveau A. Brett P. (2017). A translational synthetic biology platform for rapid access to gram-scale quantities of novel drug-like molecules. Metab. Eng. 42 185–193. 10.1016/j.ymben.2017.06.012 28687337 Ribaudo G. Coghi P. Yang L. J. Ng J. P. L. Mastinu A. Memo M. (2021). Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD). Nat. Prod. Res. 33 1–6. 10.1080/14786419.2021.1925894 33977847 Riganti C. Doublier S. Viarisio D. Miraglia E. Pescarmona G. Ghigo D. (2009). Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1α and P-glycoprotein overexpression. Br. J. Pharmacol. 156 1054–1066. 10.1111/j.1476-5381.2009.00117.x 19298255 Ro D. K. Ouellet M. Paradise E. M. Burd H. Eng D. Paddon C. J. (2008). Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid. BMC Biotechnol. 8:1–14. 10.1186/1472-6750-8-83 18983675 Ro D. K. Paradise E. M. Quellet M. Fisher K. J. Newman K. L. Ndungu J. M. (2006). Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440 940–943. 10.1038/nature04640 16612385 Roh J. L. Kim E. H. Jang H. Shin D. (2017). Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 11 254–262. 10.1016/j.redox.2016.12.010 28012440 Rolta R. Salaria D. Kumar V. Sourirajan A. Dev K. (2020). Phytocompounds of Rheum emodi, Thymus serpyllum and Artemisia annua inhibit COVID-19 binding to ACE2 receptor: in silico approach. Curr. Pharmacol. Rep. 10.21203/rs.3.rs-30938/v1 [Epub ahead of print], Sa G. Mi M. He-chun Y. Ben-ye L. Guo-feng L. Kang C. (2001). Effects of ipt gene expression on the physiological and chemical characteristics of Artemisia annua L. Plant Sci. 160 691–698. 10.1016/S0168-9452(00)00453-2 Sarma B. Willmes C. Angerer L. Adam C. Becker J. C. Kervarrec T. (2020). Artesunate affects T antigen expression and survival of virus-positive merkel cell carcinoma. Cancers 12 1–15. 10.3390/cancers12040919 32283634 Schramek N. Wang H. Römisch-Margl W. Keil B. Radykewicz T. Winzenhörlein B. (2010). Artemisinin biosynthesis in growing plants of Artemisia annua. a 13CO2 study. Phytochemistry 71 179–187. 10.1016/j.phytochem.2009.10.015 19932496 Sehailia M. Chemat S. (2020). Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19. J. Biomol. Struct. Dyn. 39 6184–6194. 10.1080/07391102.2020.1796809 32696720 Shandilya A. Chacko S. Jayaram B. Ghosh I. (2013). A plausible mechanism for the antimalarial activity of artemisinin: a computational approach. Sci. Rep. 3 1–7. 10.1038/srep02513 23985481 Shen Q. Chen Y. F. Wang T. Wu S. Y. Lu X. Zhang L. (2012). Overexpression of the cytochrome P450 monooxygenase (cyp71av1) and cytochrome P450 reductase (cpr) genes increased artemisinin content in Artemisia annua (asteraceae). Genet. Mol. Res. 11 3298–3309. 10.4238/2012.September.12.13 23079824 Shen Q. Yan T. Fu X. Tang K. (2016). Transcriptional regulation of artemisinin biosynthesis in Artemisia annua L. Sci. Bull. 61 18–25. 10.1007/s11434-015-0983-9 Shi R. Cui H. Bi Y. Huang X. Song B. Cheng C. (2015). Artesunate altered cellular mechanical properties leading to deregulation of cell proliferation and migration in esophageal squamous cell carcinoma. Oncol. Lett. 9 2249–2255. 10.3892/ol.2015.2982 26137051 Singh N. P. Lai H. C. (2004). Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 24 2277–2280. Singh N. P. Verma K. B. (2002). Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch. Oncol. 10 279–280. 10.2298/AOO0204279S Singhal T. (2020). A review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr. 87 281–286. 10.1007/s12098-020-03263-6 32166607 Song J. Zhang L. Xu Y. Yang D. Yang S. Zhang W. (2021). The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro. Biochem. Pharmacol. 183:114302. 10.1016/j.bcp.2020.114302 33121927 Srivastava N. K. Sharma S. (1990). Influence of micronutrient imbalance on growth and artemisinin content in Artemisia annua. Indian J. Pharm. Sci. 52 225–227. Su T. Li F. Guan J. Liu L. Huang P. Wang Y. (2019). Artemisinin and its derivatives prevent helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling. Phytomedicine 63:152968. 10.1016/j.phymed.2019.152968 31280140 Subedi A. Futamura Y. Nishi M. Ryo A. Watanabe N. Osada H. (2016). High-throughput screening identifies artesunate as selective inhibitor of cancer stemness: involvement of mitochondrial metabolism. Biochem. Biophys. Res. Commun. 477 737–742. 10.1016/j.bbrc.2016.06.128 27363336 Sundar S. N. Marconett C. N. Doan V. B. Willoughby J. A. Firestone G. L. (2008). Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 29 2252–2258. 10.1093/carcin/bgn214 18784357 Tanaka T. Narazaki M. Kishimoto T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 6:a016295. Tang K. Shen Q. Yan T. Fu X. (2014). Transgenic approach to increase artemisinin content in Artemisia annua L. Plant Cell Rep. 33 605–615. 10.1007/s00299-014-1566-y 24413765 Teoh K. H. Polichuk D. R. Reed D. W. Nowak G. Covello P. S. (2006). Artemisia annua L. (asteraceae) trichome-specific cDNAs reveal CYP71AV1, a cytochrome P450 with a key role in the biosynthesis of the antimalarial sesquiterpene lactone artemisinin. FEBS Lett. 580 1411–1416. 10.1016/j.febslet.2006.01.065 16458889 Thanaketpaisarn O. Waiwut P. Sakurai H. Saiki I. (2011). Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. Int. J. Oncol. 39 279–285. 10.3892/ijo.2011.1017 21537836 Tilley L. Straimer J. Gnädig N. F. Ralph S. A. Fidock D. A. (2016). Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol. 32 682–696. 10.1016/j.pt.2016.05.010 27289273 Tin A. S. Sundar S. N. Tran K. Q. Park A. H. Poindexter K. M. Firestone G. L. (2012). Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer. Drugs 23 370–379. 10.1097/CAD.0b013e32834f6ea8 22185819 Ting H. M. Wang B. Rydén A. M. Woittiez L. Van Herpen T. Verstappen F. W. A. (2013). The metabolite chemotype of Nicotiana benthamiana transiently expressing artemisinin biosynthetic pathway genes is a function of CYP71AV1 type and relative gene dosage. New Phytol. 199 352–366. 10.1111/nph.12274 23638869 Tong Y. Liu Y. Zheng H. Zheng L. Liu W. Wu J. (2016). Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget 7 31413–31428. 10.18632/oncotarget.8920 27119499 Tran K. Q. Tin A. S. Firestone G. L. (2014). Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-κB transcriptional signaling. Anticancer. Drugs 25 270–281. 10.1097/CAD.0000000000000054 24296733 Tran T. H. Nguyen A. N. Kim J. O. Yong C. S. Nguyen C. N. (2016). Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers. Artif. Cells Nanomed. Biotechnol. 44 1979–1987. 10.3109/21691401.2015.1129616 26754823 Tsuruta H. Paddon C. J. Eng D. Lenihan J. R. Horning T. Anthony L. C. (2009). High-level production of amorpha-4, 11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli. PLoS One 4:4489. 10.1371/journal.pone.0004489 19221601 Tu Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17 1217–1220. 10.1038/nm.2471 21989013 Uckun F. M. Saund S. Windlass H. Trieu V. (2021). Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug. Front. Pharmacol. 12:1–5. 10.3389/fphar.2021.649532 33815126 Ulhaq Z. S. Soraya G. V. (2020). Interleukin-6 as a potential biomarker of COVID-19 progression. Med. Mal. Infect. 50 382–383. 10.1016/j.medmal.2020.04.002 32259560 Uzun T. Toptas O. (2020). Artesunate: could be an alternative drug to chloroquine in COVID-19 treatment? Chin. Med. 15:54. 10.1186/s13020-020-00336-8 32514287 van Herpen T. W. J. M. Cankar K. Nogueira M. Bosch D. Bouwmeester H. J. Beekwilder J. (2010). Nicotiana benthamiana as a production platform for artemisinin precursors. PLoS One 5:14222. 10.1371/journal.pone.0014222 21151979 Våtsveen T. K. Myhre M. R. Steen C. B. Wälchli S. Lingjærde O. C. Bai B. (2018). Artesunate shows potent anti-tumor activity in B-cell lymphoma. J. Hematol. Oncol. 11 1–12. 10.1186/s13045-018-0561-0 29458389 Velazquez-Salinas L. Verdugo-Rodriguez A. Rodriguez L. L. Borca M. V. (2019). The role of interleukin 6 during viral infections. Front. Microbiol. 10:6–11. 10.3389/fmicb.2019.01057 31134045 Verma I. M. Stevenson J. K. Schwarz E. M. Van Antwerp D. (1995). Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 9 2723–2735. Verma S. Das P. Kumar V. L. (2017). Chemoprevention by artesunate in a preclinical model of colorectal cancer involves down regulation of β-catenin, suppression of angiogenesis, cellular proliferation and induction of apoptosis. Chem. Biol. Interact. 278 84–91. 10.1016/j.cbi.2017.10.011 29031619 Verma S. Twilley D. Esmear T. Oosthuizen C. B. Reid A. M. Nel M. (2020). Anti-SARS-CoV natural products with the potential to inhibit SARS-CoV-2 (COVID-19). Front. Pharmacol. 11:1–20. 10.3389/fphar.2020.561334 33101023 Verpoorte R. Memelink J. (2002). Engineering secondary metabolite production in plants. Curr. Opin. Biotechnol. 13 181–187. 10.1016/S0958-1669(02)00308-7 Vranová E. Coman D. Gruissem W. (2013). Network analysis of the MVA and MEP pathways for isoprenoid synthesis. Annu. Rev. Plant Biol. 64 665–700. 10.1146/annurev-arplant-050312-120116 23451776 Wallaart T. E. Bouwmeester H. J. Hille J. Poppinga L. Maijers N. C. A. (2001). Amorpha-4,11-diene synthase: cloning and functional expression of a key enzyme in the biosynthetic pathway of the novel antimalarial drug artemisinin. Planta 212 460–465. 10.1007/s004250000428 11289612 Wang B. Beyraghdar Kashkooli A. Sallets A. Ting H. M. de Ruijter N. C. A. Olofsson L. (2016). Transient production of artemisinin in Nicotiana benthamiana is boosted by a specific lipid transfer protein from a. annua. Metab. Eng. 38 159–169. 10.1016/j.ymben.2016.07.004 27421621 Wang B. Hou D. Liu Q. Wu T. Guo H. Zhang X. (2015). Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51. Cancer Biol. Ther. 16 1548–1556. 10.1080/15384047.2015.1071738 26176175 Wang J. Huang L. Li J. Fan Q. Long Y. Li Y. (2010). Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 5:e9582. 10.1371/journal.pone.0009582 20221395 Wang J. Zhang C. J. Chia W. N. Loh C. C. Y. Li Z. Lee Y. M. (2015). Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat. Commun. 6:10111. 10.1038/ncomms10111 26694030 Wang J. S. Wang M. J. Lu X. Zhang J. Liu Q. X. Zhou D. (2020). Artesunate inhibits epithelial-mesenchymal transition in non-small-cell lung cancer (NSCLC) cells by down-regulating the expression of BTBD7. Bioengineered 11 1197–1207. 10.1080/21655979.2020.1834727 33108235 Wang K. Zhang Z. Wang M. Cao X. Qi J. Wang D. (2019). Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells. Drug Des. Devel. Ther. 13 2135–2144. 10.2147/DDDT.S199459 31456633 Wang L. Li J. Shi X. Li S. Tang P. M.-K. Li Z. (2019). Antimalarial dihydroartemisinin triggers autophagy within HeLa cells of human cervical cancer through Bcl-2 phosphorylation at Ser70. Phytomedicine 52 147–156. 10.1016/j.phymed.2018.09.221 30599894 Wang L. Liu L. Wang J. Chen Y. (2017). Inhibitory effect of artesunate on growth and apoptosis of gastric cancer cells. Arch. Med. Res. 48 623–630. 10.1016/j.arcmed.2018.03.004 29544887 Wang S. J. Gao Y. Chen H. Kong R. Jiang H. C. Pan S. H. (2010). Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett. 293 99–108. 10.1016/j.canlet.2010.01.001 20137856 Wang S.-J. Sun B. Cheng Z.-X. Zhou H.-X. Gao Y. Kong R. (2011). Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway. Cancer Chemother. Pharmacol. 68 1421–1430. 10.1007/s00280-011-1643-7 21479633 Wani K. I. Choudhary S. Zehra A. Naeem M. Weathers P. Aftab T. (2021). Enhancing artemisinin content in and delivery from Artemisia annua: a review of alternative, classical, and transgenic approaches. Planta 254 1–15. 10.1007/s00425-021-03676-3 34263417 Weathers L. D. (2003). Tetraploid Artemisia annua hairy roots produce more artemisinin than diploids. Plant Cell Rep. 21 809–813. 10.1007/s00299-003-0587-8 12789527 Weathers P. J. Bunk G. McCoy M. C. (2005). The effect of phytohormones on growth and artemisinin production in Artemisia annua hairy roots. Vitr. Cell. Dev. Biol. Plant 41 47–53. 10.1079/IVP2004604 Wen L. Liu L. Wen L. Yu T. Wei F. (2018). Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation. Breast Cancer 25 681–686. 10.1007/s12282-018-0873-5 29797234 Westfall P. J. Pitera D. J. Lenihan J. R. Eng D. Woolard F. X. Regentin R. (2012). Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin. Proc. Natl. Acad. Sci. U.S.A. 109 111–118. 10.1073/pnas.1110740109 22247290 Williamson G. Kerimi A. (2020). Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction. Biochem. Pharmacol. 178:114123. 10.1016/j.bcp.2020.114123 32593613 Willoughby J. A. Sundar S. N. Cheung M. Tin A. S. Modiano J. Firestone G. L. (2009). Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J. Biol. Chem. 284 2203–2213. 10.1074/jbc.M804491200 19017637 Wu J. Hu D. Yang G. Zhou J. Yang C. Gao Y. (2011). Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J. Cell. Biochem. 112 1938–1948. 10.1002/jcb.23114 21445878 Wu L. Cheng Y. Deng J. Tao W. Ye J. (2019). Dihydroartemisinin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cell by upregulating tumor necrosis factor via JNK/NF-κB pathways. evidence-based Complement. Altern. Med. 2019:327. 10.1155/2019/9581327 31534470 Wu T. Wu S. Yin Q. Dai H. Li S. Dong F. (2011). Biosynthesis of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli through introducing mevalonate pathway. Shengwu Gongcheng Xuebao/Chinese J. Biotechnol. 27 1040–1048. Xie D. Y. Ma D. M. Judd R. Jones A. L. (2016). Artemisinin biosynthesis in Artemisia annua and metabolic engineering: questions, challenges, and perspectives. Phytochem. Rev. 15 1093–1114. 10.1007/s11101-016-9480-2 Xiong Z. Sun G. Zhu C. Cheng B. Zhang C. Ma Y. (2010). Artemisinin, an anti-malarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-κB signaling. Eur. J. Pharmacol. 649 277–284. 10.1016/j.ejphar.2010.09.018 20863781 Xu H. He Y. Yang X. Liang L. Zhan Z. Ye Y. (2007). Anti-malarial agent artesunate inhibits TNF-α-induced production of proinflammatory cytokines via inhibition of NF-κB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology 46 920–926. 10.1093/rheumatology/kem014 17314215 Yan A. Pan J. An L. Gan Y. Feng H. (2012). The responses of trichome mutants to enhanced ultraviolet-B radiation in Arabidopsis thaliana. J. Photochem. Photobiol. B Biol. 113 29–35. 10.1016/j.jphotobiol.2012.04.011 22647943 Yang C. Q. Fang X. Wu X. M. Mao Y. B. Wang L. J. Chen X. Y. (2012). Transcriptional regulation of plant secondary metabolism. J. Integr. Plant Biol. 54 703–712. 10.1111/j.1744-7909.2012.01161.x 22947222 Yang N. Di Tan S. H. Ng S. Shi Y. Zhou J. Tan K. S. W. (2014). Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J. Biol. Chem. 289 33425–33441. 10.1074/jbc.M114.564567 25305013 Yang R.-Y. Feng L.-L. Yang X.-Q. Yin L.-L. Xu X.-L. Zeng Q.-P. (2008). Quantitative transcript profiling reveals down-regulation of a sterol pathway relevant gene and overexpression of artemisinin biogenetic genes in transgenic Artemisia annua plants. Planta Med. 74 1510–1516. 10.1055/s-2008-1081333 18816428 Yao Z. Bhandari A. Wang Y. Pan Y. Yang F. Chen R. (2018). Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line. Biochem. Biophys. Res. Commun. 501 636–642. 10.1016/j.bbrc.2018.05.026 29738772 Ye V. M. Bhatia S. K. (2012). Metabolic engineering for the production of clinically important molecules: omega-3 fatty acids, artemisinin, and taxol. Biotechnol. J. 7 20–33. 10.1002/biot.201100289 22021189 Yin S. Yang H. Zhao X. Wei S. Tao Y. Liu M. (2020). Antimalarial agent artesunate induces G0/G1 cell cycle arrest and apoptosis via increasing intracellular ROS levels in normal liver cells. Hum. Exp. Toxicol. 39 1681–1689. 10.1177/0960327120937331 32633561 Yin X. Liu Y. Qin J. Wu Y. Huang J. Zhao Q. (2021). Artesunate suppresses the proliferation and development of estrogen receptor-α-positive endometrial cancer in HAND2-dependent pathway. Front. Cell Dev. Biol. 8:1–14. 10.3389/fcell.2020.606969 33511117 Yu C. Sun P. Zhou Y. Shen B. Zhou M. Wu L. (2019). Inhibition of AKT enhances the anti-cancer effects of artemisinin in clear cell renal cell carcinoma. Biomed. Pharmacother. 118:109383. 10.1016/j.biopha.2019.109383 31545251 Yu L. Chen J. F. Shuai X. Xu Y. Ding Y. Zhang J. (2016). Artesunate protects pancreatic beta cells against cytokine-induced damage via SIRT1 inhibiting NF-κB activation. J. Endocrinol. Invest. 39 83–91. 10.1007/s40618-015-0328-1 26062521 Yuan Y. Liu W. Zhang Q. Xiang L. Liu X. Chen M. (2015). Overexpression of artemisinic aldehyde Δ11 (13) reductase gene-enhanced artemisinin and its relative metabolite biosynthesis in transgenic Artemisia annua L. Biotechnol. Appl. Biochem. 62 17–23. 10.1002/bab.1234 25040292 Zeng Q. P. Zhang P. Z. (2011). Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide Biol. Chem. 24 110–112. 10.1016/j.niox.2010.12.005 21168521 Zeng X. Zhang Y. Wang K. Tao L. Zou M. Chen N. (2017). Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca2+–NFATc1 signaling pathway and prevents ovariectomy-induced bone loss. Biochem. Pharmacol. 124 57–68. 10.1016/j.bcp.2016.10.007 27789216 Zhang H. T. Wang Y. L. Zhang J. Zhang Q. X. (2014). Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53. Tumor Biol. 38 639–646. 10.1002/cbin.10244 24446394 Zhang J. Sun X. Wang L. Wong Y. K. Lee Y. M. Zhou C. (2018). Artesunate-induced mitophagy alters cellular redox status. Redox Biol. 19 263–273. 10.1016/j.redox.2018.07.025 30196190 Zhang L. Jing F. Li F. Li M. Wang Y. Wang G. (2009). Development of transgenic Artemisia annua (chinese wormwood) plants with an enhanced content of artemisinin, an effective anti-malarial drug, by hairpin-RNA-mediated gene silencing. Biotechnol. Appl. Biochem. 52:199. 10.1042/BA20080068 18564056 Zhang L. X. Liu Z. N. Ye J. Sha M. Qian H. Bu X. H. (2014). Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression. Cell Biol. Int. 38 639–646. Zhang P. Luo H. S. Li M. Tan S. Y. (2015). Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2. Onco. Targets. Ther. 8 845–854. 10.2147/OTT.S81041 25945055 Zhang Y. Nowak G. Reed D. W. Covello P. S. (2011). The production of artemisinin precursors in tobacco. Plant Biotechnol. J. 9 445–454. 10.1111/j.1467-7652.2010.00556.x 20723135 Zhang Y. Teoh K. H. Reed D. W. Maes L. Goossens A. Olson D. J. H. (2008). The molecular cloning of artemisinic aldehyde Δ11(13) reductase and its role in glandular trichome-dependent biosynthesis of artemisinin in Artemisia annua. J. Biol. Chem. 283 21501–21508. 10.1074/jbc.M803090200 18495659 Zhang Y. S. Ye H. C. Liu B. Y. Wang H. Li G. F. (2005). Exogenous GA3 and flowering induce the conversion of artemisinic acid to artemisinin in Artemisia annua plants. Russ. J. Plant Physiol. 52 58–62. 10.1007/s11183-005-0009-6 Zhao F. Vakhrusheva O. Markowitsch S. D. Slade K. S. Tsaur I. Cinatl J. (2020). Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction. Cells 9 1–19. 10.3390/cells9122643 33316936 Zhao J. Davis L. C. Verpoorte R. (2005). Elicitor signal transduction leading to production of plant secondary metabolites. Biotechnol. Adv. 23 283–333. 10.1016/j.biotechadv.2005.01.003 15848039 Zhao Y. Jiang W. Li B. Yao Q. Dong J. Cen Y. (2011). Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G 2/M phase. Int. Immunopharmacol. 11 2039–2046. 10.1016/j.intimp.2011.08.017 21907831 Zheng Y.-Y. Ma Y. T. Zhang J. Y. Xie X. (2020). COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17 259–260. 10.1038/s41569-020-0360-5 32139904 Zhou H. J. Wang W. Q. Wu G. D. Lee J. Li A. (2007). Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul. Pharmacol. 47 131–138. 10.1016/j.vph.2007.05.002 17581794 Zhou M. Memelink J. (2016). Jasmonate-responsive transcription factors regulating plant secondary metabolism. Biotechnol. Adv. 34 441–449. 10.1016/j.biotechadv.2016.02.004 26876016 Zhou X. Chen Y. Wang F. Wu H. Zhang Y. Liu J. (2020a). Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells. Chem. Biol. Interact. 331:109273. 10.1016/j.cbi.2020.109273 33002460 Zhou X. Sun W. J. Wang W. M. Chen K. Zheng J. H. Lu M. D. (2013). Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anticancer. Drugs 24 920–927. 10.1097/CAD.0b013e328364a109 23958790 Zhou X. Zijlstra S. N. Soto-Gamez A. Setroikromo R. Quax W. J. (2020b). Artemisinin derivatives stimulate DR5-specific TRAIL-induced apoptosis by regulating wildtype P53. Cancers (Basel). 12:2514. 10.3390/cancers12092514 32899699 Zhou Y. Gilmore K. Ramirez S. Settels E. Gammeltoft K. A. Pham L. V. (2021). In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. Sci. Rep. 11 1–14. 10.1038/s41598-021-93361-y 34272426 Zhou Y. Wang X. Zhang J. He A. Wang Y. L. Han K. (2017). Artesunate suppresses the viability and mobility of prostate cancer cells through UCA1, the sponge of miR-184. Oncotarget 8 18260–18270. 10.18632/oncotarget.15353 28209917 Zhu S. Liu W. Ke X. Li J. Hu R. Cui H. (2014). Artemisinin reduces cell proliferation and induces apoptosis in neuroblastoma. Oncol. Rep. 32 1094–1100. 10.3892/or.2014.3323 25017372 Zhu Z. Cai T. Fan L. Lou K. Hua X. Huang Z. (2020). Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int. J. Infect. Dis. 95 332–339. 10.1016/j.ijid.2020.04.041 32334118 Zuo W. Wang Z. Z. Xue J. (2014). Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression. Int. J. Mol. Sci. 15 14298–14312. 10.3390/ijms150814298 25196524

https://clinicaltrials.gov/

https://www.chictr.org.cn/